

Title: A genome-wide association analysis of 2,622,830 individuals reveals new pathogenic pathways in gout

Tanya J. Major^{1,2,3,^}, Riku Takei^{2,3,4,^}, Hirotaka Matsuo^{2,3,5,^,#}, Megan P. Leask^{3,4,^}, Ruth K. Topless^{1,^}, Yuya Shirai^{2,6,^}, Zhiqiang Li⁷, Aichang Ji^{2,8,9}, Murray J. Cadzow¹, Nicholas A. Sumpter⁴, Marilyn E. Merriman⁴, Amanda J. Phipps-Green¹, Mariana Urquiaga⁴, Eric E. Kelley¹⁰, Rachel D. King¹⁰, Sara E. Lewis¹⁰, Brooke A. Maxwell¹⁰, Wen-Hua Wei^{1,2,11}, Sally P.A. McCormick¹, Richard J. Reynolds⁴, Kenneth G. Saag⁴, Matthew J. Bixley¹, Tayaza Fadason¹², Justin M. O'Sullivan^{12,13,14,15}, Lisa K. Stamp^{2,3,16}, Nicola Dalbeth^{2,3,17}, Abhishek Abhishek^{3,18}, Michael Doherty^{3,18}, Edward Roddy^{3,19,20}, Lennart T.H. Jacobsson^{3,21}, Meliha C. Kapetanovic^{3,22}, Olle Melander^{3,23,24}, Mariano Andrés^{3,25,26}, Fernando Pérez-Ruiz^{3,27}, Rosa J Torres^{3,28,29}, Timothy Radstake^{3,30}, Timothy L. Jansen^{3,31}, Matthijs Janssen^{3,31}, Leo A.B. Joosten^{3,32,33}, Ruiqi Liu³², Orsi Gaal³³, Tania O. Crişan^{3,33,34}, Simona Rednic³⁴, Fina Kurreeman^{3,35}, Tom W.J. Huizinga^{3,35}, René Toes^{3,35}, Frédéric Liote^{3,36}, Pascal Richette^{3,36}, Thomas Bardin^{2,3,36}, Hang Korng Ea^{3,37}, Tristan Pascart^{3,38}, Geraldine M. McCarthy^{3,39}, Laura Helbert³⁹, Blanka Stibůrková^{2,3,40,41}, Anne-K. Tausche^{3,42}, Till Uhlig^{3,43}, Véronique Vitart⁴⁴, Thibaud S. Boutin⁴⁴, Caroline Hayward⁴⁴, Philip L. Riches⁴⁵, Stuart H. Ralston⁴⁵, Archie Campbell⁴⁵, Thomas M. MacDonald⁴⁶ on behalf of the FAST Study, Akiyoshi Nakayama^{2,5}, Tappei Takada^{2,47}, Masahiro Nakatochi^{2,48}, Seiko Shimizu^{2,5}, Yusuke Kawamura^{2,5}, Yu Toyoda^{2,5}, Hirofumi Nakaoka⁴⁹, Ken Yamamoto⁵⁰, Keitaro Matsuo^{51,52,53}, Nariyoshi Shinomiya^{2,5}, Kimiyoshi Ichida^{2,54}, Japan Gout Genomics Consortium[&], Chaeyoung Lee⁵⁵, Linda A. Bradbury^{3,56}, Matthew A. Brown^{3,56}, Philip C. Robinson^{3,57}, Russell R.C. Buchanan^{3,58}, Catherine L. Hill^{3,59}, Susan Lester^{3,59}, Malcolm D. Smith^{3,60}, Maureen Rischmueller^{3,59}, Hyon K. Choi⁶¹, Eli A. Stahl⁶², Jeff N. Miner⁶³, Daniel H. Solomon⁶⁴, Jing Cui⁶⁴, Kathleen M. Giacomini⁶⁵, Deanna J. Brackman⁶⁵, Eric M. Jorgenson⁶⁶, 23andMe Research Team⁶⁷, Wei Wang⁶⁸, Suyash Shringarpure⁶⁸, Alexander So^{3,69,70}, Yukinori Okada^{2,3,6,71,72,#}, Changgui Li^{2,3,8,#}, Yongyong Shi^{2,3,73,74,#}, Tony R. Merriman^{1,2,3,4,#,*}

1. Department of Biochemistry, University of Otago, Dunedin, New Zealand
2. Asia Pacific Gout Consortium
3. GlobalGout Genetics Consortium
4. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States
5. Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan
6. Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan
7. The Biomedical Sciences Institute and The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China
8. Shandong Provincial Key Laboratory of Metabolic Diseases, Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
9. The Institute of Metabolic Diseases, Qingdao University, Qingdao, Shandong, China

10. Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV, United States
11. Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand
12. Liggins Institute, University of Auckland, Auckland, New Zealand
13. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom
14. Singapore Institute for Clinical Sciences, Agency for Science Technology and Research, Singapore
15. Australian Parkinsons Mission, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
16. Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
17. Department of Medicine, University of Auckland, Auckland, New Zealand
18. Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom
19. School of Medicine, Keele University, Keele, Staffordshire, United Kingdom
20. Haywood Academic Rheumatology Centre, Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, UK
21. Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
22. Department of Clinical Sciences Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden
23. Department of Clinical Sciences, Lund University, Malmö, Sweden
24. Department of Emergency and Internal Medicine, Skåne University Hospital, Malmö, Sweden
25. Rheumatology Department, Dr Balmis General University Hospital-ISABIAL
26. Miguel Hernandez University, Alicante, Spain
27. Osakidetza, OSI-EE-Cruces, BIOBizkaia Health Research Institute and Medicine Department of Medicine and Nursery School, University of the Basque Country, Biskay Spain
28. Department of Biochemistry, Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain
29. Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.
30. Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, the Netherlands
31. Department of Rheumatology, VieCuri Medical Centre, Venlo, Netherlands
32. Department of Internal Medicine and Radboud Institute of Molecular Life Science, Radboud University Medical Center, Nijmegen, Netherlands
33. Department of Medical Genetics, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
34. Department of Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania
35. Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
36. Rheumatology Department and INSERM UMR 1132, Lariboisière Hospital, University Paris Cité, Faculté de Santé, Paris, France
37. INSERM UMR 1132, University of Paris, Paris, France
38. Department of Rheumatology, Hopital Saint-Philibert, Lille Catholic University, Lille, France
39. Department of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
40. Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic.
41. General University Hospital, Prague, Czech Republic
42. Department of Rheumatology, University Clinic 'Carl Gustav Carus' at the Technical University, Dresden, Germany
43. Center for Treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital, Oslo, Norway
44. Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
45. Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
46. Medicines Monitoring Unit (MEMO Research), Division of Molecular and Clinical Medicine, University of Dundee, Dundee, United Kingdom

47. Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan
 48. Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Aichi, Japan
 49. Department of Cancer Genome Research, Sasaki Institute, Sasaki Foundation, Tokyo, Japan.
 50. Department of Medical Biochemistry, Kurume University School of Medicine, Fukuoka, Japan
 51. Division of Cancer Epidemiology & Prevention, Aichi Cancer Center, Aichi, Japan
 52. Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Aichi, Japan
 53. The Japan Multi-Institutional Collaborative Cohort (J-MICC) Study
 54. Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
 55. Department of Bioinformatics and Life Science, Soongsil University, Seoul, South Korea
 56. Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, Australia
 57. School of Clinical Medicine, Faculty of Medicine, University of Queensland, Brisbane, Australia
 58. Department of Rheumatology, Austin Hospital, Melbourne, Victoria, Australia
 59. Rheumatology Department, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
 60. Flinders University, Adelaide, South Australia, Australia
 61. Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
 62. Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
 63. Organovo, 11555 Sorrento Valley Rd, Ste 100, San Diego, CA 92121
 64. Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
 65. Department of Bioengineering and Therapeutic Sciences and Institute for Human Genetics, University of California, San Francisco, CA, United States
 66. Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States
 67. 23andMe, Inc., Sunnyvale, CA, United States
 68. Genomics R&D, 23andMe, Inc., Sunnyvale, CA, United States
 69. Service of Rheumatology, Center Hospitalier Universitaire Vaudois, Lausanne, Switzerland
 70. University of Lausanne, Lausanne, Switzerland
 71. Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
 72. Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
 73. Affiliated Hospital of Qingdao University and Biomedical Sciences Institute of Qingdao University (Qingdao Branch of SJTU Bio-X Institutes), Qingdao University, Qingdao, China.
 74. Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
- &. A list of contributors and their affiliations appears at the end of the paper

*Corresponding Author: Tony R. Merriman tony.merriman@otago.ac.nz

^These authors contributed equally

#These authors contributed equally

Abstract

Gout is a chronic disease of monosodium urate crystal deposition in the setting of hyperuricemia that typically presents with recurrent flares of acute inflammatory arthritis that occur due to innate immune response to deposited crystals. The molecular mechanism of the progression from hyperuricemia to clinical gout is poorly understood. Here we provide insights into this progression from a genetic study of 2.6 million people, including 120,282 people with gout. We detected 376 loci and 410 genetically independent signals (148 new loci in urate and gout). We identified 1,768 candidate genes with subsequent pathway analysis revealing urate metabolism, type 2 diabetes, and chromatin modification and structure as top pathways in gout. Genes located within or statistically linked to significant GWAS loci were prioritized for their potential to control the progression from hyperuricemia to gout. This identified strong candidate immune genes involved in epigenetic remodelling, cell osmolarity, and regulation of NLRP3-inflammasome activity. The genetic association signal at *XDH*, encoding the urate-producing enzyme xanthine oxidoreductase (XOR), co-localizes with genetic control of *XDH* expression, but only in the prostate. We demonstrate XOR activity and urate production in the mouse prostate, and use single-cell RNA sequence data to propose a model of urate reuptake, synthesis, and secretion by the prostate. The gout-associated loci were over-represented for genes implicated in clonal hematopoiesis of indeterminate potential (CHIP) and Mendelian randomization analysis provided evidence for a causal role of CHIP in gout. In concert with implication of epigenomic regulators, this provides support for epigenomic remodelling as causal in gout. We provide new insights into the molecular pathogenesis of gout and identify an array of candidate genes for a role in the inflammatory process of gout.

Introduction

Gout is an important public health issue of increasing prevalence¹ and burden² that is exacerbated by co-morbidity with cardiometabolic and renal disease³. Prevalence is approximately four-fold greater in men than in women¹. It typically presents as recurrent self-limiting attacks of extremely painful acute inflammatory arthritis (termed ‘gout flares’). Gout is a chronic disease of monosodium urate (MSU) crystal deposition in joints and other structures that occurs in the setting of elevated serum urate levels (hyperuricemia)⁴. The gout flare is initiated when MSU crystals interact with resident macrophages to form and activate the NOD-like receptor protein 3 (NLRP3) inflammasome, which results in production of mature IL-1 β and IL-18⁵. The inflammatory response is then amplified by the recruitment and activation of innate immune cells such as neutrophils, with the resolution phase mediated by processes including anti-inflammatory cytokines and aggregated neutrophil extracellular traps⁶. Soluble urate trains the immune system⁷ to have increased activity and response to MSU crystals through durable epigenetic modifications⁸.

Large genome-wide association studies (GWAS) have provided insight into the molecular mechanisms of urate control, with genetic variation in loci containing renal and intestinal urate transporters being prominent (e.g. *SLC2A9*, *ABCG2*, *SLC22A12*), with the kidney and liver the main organs in which genetic control is exerted⁹. In contrast, GWAS in gout have been relatively small⁹⁻¹⁵, the largest studies comprise 13,179⁹ and 37,105¹⁶ individuals with gout and identified 27 and 52 gout-associated genes, respectively; the majority of which also associate with urate levels. Whilst understanding the genetic and molecular control of serum urate is important in gout, most individuals with hyperuricemia do not develop gout (only up to 36%^{17,18}) and many individuals with hyperuricemia who have not experienced a gout flare

have imaging-confirmed monosodium urate crystal deposits.¹⁹ Subclinical inflammation is associated with these deposits, indicating other factors must be involved in developing symptomatic gout²⁰. Estimates of serum urate heritability from twin studies range from 45 to 73%, but there are no credible estimates of the heritability of gout based on twin studies²⁰. Heritability calculated using genome-wide genotype data in a cohort of unrelated European individuals was estimated at 28 to 30%, which is consistent with a recently-reported heritability estimate (27.9%) of clinically-defined gout in Japanese populations²¹, suggesting gout may be less heritable than hyperuricemia. Nevertheless genetic studies should be able to elucidate mechanisms involved in progressing from hyperuricemia to gout²².

There is some evidence for genetic variants controlling the progression from hyperuricemia to gout. GWAS in gout comparing to individuals with asymptomatic hyperuricemia have identified a small number of loci^{10,23,24} (most of which also associate with serum urate levels^{9,25}), and a Polynesian-specific variant in *IL-37* associates with gout compared to asymptomatic hyperuricemia²⁶. However, these loci cannot necessarily be interpreted as controlling the progression from hyperuricemia to symptomatic gout because hyperuricemia is defined by a single urate measure in each study, which does not allow accounting for the lifetime burden of urate²⁷. Candidate gene studies have associated variants in inflammatory genes with gout, but none are widely replicated²⁰. We present findings from the largest GWAS in gout to date utilizing 120,282 cases and 2,502,548 controls over four ancestral groups. The findings illuminate previously unidentified candidate pathways with the potential to control the progression from hyperuricemia to clinical gout.

Results

Study overview

The study design is summarized in **Figure S1**. This study comprised GWAS in four ancestral groups (African, East Asian, European, Latinx) and a trans-ancestry meta-analysis, each including sex-specific analyses. Summary statistics were amalgamated from 120,282 people with and 2,502,548 people without gout. The effect of a polygenic risk score on risk and prediction of gout was evaluated, as was genome-wide genetic correlation with other phenotypes. Follow-up analyses included identification of candidate genes by co-localizing signals of association with expression quantitative trait loci (eQTL), identifying genes with candidate missense variants, and genes identified by MAGMA²⁸. These candidate genes were applied to pathway analysis. A prioritization scheme identified candidate genes for the progression from hyperuricemia to gout. Mechanistic studies included investigation of the role of xanthine oxidoreductase in the prostate in synthesizing urate, and the evaluation of a causal role for the clonal hematopoiesis of indeterminate potential (CHIP) pathway in gout.

Identification of GWAS signals

Single- and trans-ancestry genome-wide analyses

We carried out fixed-effect inverse-variance weighted GWAS meta-analyses for gout in four ancestral groups (African (AFR) – 3,052 cases and 77,891 controls; East Asian (EAS) – 10,729 cases and 82,807 controls; European (EUR) – 100,661 cases and 2,106,003 controls; and Latinx (LAT) – 5,840 cases and 235,847 controls) (**Table S1**). The four GWAS were conducted using imputed genotypes that included only biallelic single nucleotide polymorphisms (SNPs) with a minor allele frequency > 0.1% (**Methods** and **Table S1**). The African meta-analysis included 24,649,233 SNPs, the East Asian meta-analysis included

10,194,540 SNPs, the European meta-analysis included 13,443,610 SNPs, and the Latinx meta-analysis included 18,956,225 SNPs. A trans-ancestry meta-analysis of the variants present in all four ancestry-specific GWAS (6,386,511 SNPs) was also conducted to maximize locus discovery by increased sample size, and it comprised 120,282 cases and 2,502,548 controls. Whilst there was some indication of inflation of GWAS test statistics ($\lambda_{GC} = 1.050_{AFR}, 1.121_{EAS}, 1.611_{EUR}, 1.105_{LAT}$), linkage disequilibrium (LD) score regression analysis revealed no evidence of inflation due to factors such as population structure (LD score intercept = $1.025_{AFR}, 1.049_{EAS}, 1.026_{EUR}, 1.048_{LAT}$), with the elevated λ_{GC} observed in the European GWAS likely being due to polygenicity between individual cohorts contributing to the ancestry-specific meta-analysis²⁹.

Identification of significant loci and independent signals

A total of 296 genome-wide significant loci (defined as a genomic segment with ≥ 1 lead variant(s) that define a genetically independent signal) were detected in the trans-ancestry meta-analysis ($\log_{10}BF \geq 6$), 20 with >1 genetically-independent signal, resulting in 318 independent genome-wide significant signals. In the separate ancestry GWAS, two genome-wide significant loci were detected in the African GWAS, 10 in the East Asian GWAS, 277 in the European GWAS (13 with multiple signals resulting in 291 independent lead SNPs), and ten in the Latinx GWAS (**Figure 1; Figure S1, S2; Table S2**). There was a total of 339 non-overlapping loci and 365 genetically independent signals across all analyses. Only two loci were common to all ancestral-specific analyses (**Figure 1**), both on chromosome 4 and containing the well-studied *SLC2A9* and *ABCG2* genes²⁰. The *ABCG2* locus had the strongest statistical evidence for association with gout in the East Asian, European, Latinx, and trans-ancestry GWAS. A total of 119 loci were unique to one of the five GWAS conducted. Where

a locus was identified across more than one of the five GWAS, but there was a different lead SNP between the ancestries, the majority of the divergent lead SNPs were in high linkage disequilibrium ($r^2 \geq 0.8$; 93 of 139 loci; **Table S2**). For the identified lead variants, there was strong correlation between effects on serum urate level in the UK Biobank and gout risk (Pearson correlation $r = 0.92$; **Figure S3**).

Sex-stratified analyses

The prevalence of gout is at least three to four-fold greater in men than women^{1,30}. Therefore, we conducted sex-stratified GWAS for each of the four ancestral groups and the trans-ancestry meta-analysis. In each ancestry-specific analysis there were fewer female gout cases than male gout cases (ranging from a 1:2 ratio to a 1:23 ratio of women to men; **Table S1**). A total of 247 loci were identified in the male-only trans-ancestry meta-analysis (19 with multiple signals resulting in 266 independent genetic associations) and 15 significant loci were identified in the female-only trans-ancestry meta-analysis (17 independent signals) (**Table S2**). Across all ancestries there was a total of 299 independent signals in the male-only analyses and 26 independent signals in the female-only analyses; 29 of the male-only loci (36 signals) and 8 of the female-only loci were not detected in the full (combined sexes) analyses. One locus was detected in both the male-only and female-only analyses, but not the full (combined sexes) analysis (**Figure 1**). This was due to heterogeneity between the male-only and female-only signals (**Table S4**).

Of the 410 genetically independent signals identified across all analyses, 44 (representing 36 loci) had significant heterogeneity ($P < 1 \times 10^{-6}$) between the male-only and female-only results, with effect sizes greater in men for all 36 loci (**Table S3**). Thirty-two (89%) had

previously been associated with urate⁹ and include the 10 loci with the strongest effects on urate³¹ (*SLC2A9*, *ABCG2*, *SLC17A1*, *SLC16A9*, *GCKR*, *SLC22A11*, *INHBC*, *RREB1*, *PDZK1*, *SLC22A12*). *ABCG2* was heterogenous in all datasets excepting African, and *SLC2A9* was heterogenous in the trans-ancestry meta-analysis and European GWAS. Of the 32 loci previously associated with urate, 13 had also been reported as exhibiting heterogeneity between sexes in urate control⁹, with ten having a stronger effect in men and three in women (*SLC2A9*, *AICF*, *IGF1R*).

Previously unreported loci

Of the 376 loci identified across all analyses, 148 (four with two independent signals) have not previously had any variant within the locus boundaries associated with urate or gout. Thus, these 148 loci can be considered newly identified associations with gout (**Table S4**). Of the remaining 228 loci, 143 had the same lead SNP or were in high LD ($r^2 \geq 0.8$), 64 in low to moderate LD ($0.1 \leq r^2 < 0.8$), and 21 were in no linkage disequilibrium ($r^2 < 0.1$) with a SNP previously reported to be associated with serum urate or gout (**Table S4**). Of the 30 loci with >1 independent signal, 18 loci (19 independent signals) had no linkage disequilibrium ($r^2 < 0.1$) between the previously reported SNP(s) at the locus and one of the independent lead SNPs. Thus, 188 (148 + 21 + 19) of the independent signals can also be considered newly identified gout associations.

Risk prediction and genetic relationships

Polygenic risk score and risk of gout

Gout polygenic risk scores (PRS) consisting of 289 SNPs from the European and 316 from the trans-ancestry GWAS, weighted by effect size, were generated and applied to the UK

Biobank European-ancestry cohort to assess how well the GWAS results predict gout status (**Table S5**). The risk score values were split into ten bins with equal ranges, and gout prevalence increased across these ten risk score bins from 0.0 to 24.3% and 0.0 to 41.7%, respectively for the European and trans-ancestry scores (**Figure 2; Figure S4; Table S5**). Compared to the risk score bin that included the most individuals, age- and sex-adjusted odds-ratios (ORs) ranged from 0.22 [95% CI 0.11; 0.45] and 0.07 [0.02; 0.28], for European and trans-ancestry respectively, in the lowest risk score bin, to 20.7 [9.2; 46.8] and 50.0 [20.4; 122.6], respectively, in the highest risk score bin. For comparison, male sex conferred a gout risk of 13.9 [12.7; 15.1]. Male prevalence of gout in the highest European and trans-ancestry risk score bins was 39.1% (OR = 23.7 [10.1; 55.4]) and 58.8% (OR = 60.7 [22.7; 162.5]), respectively. While there were no females with gout in the highest bin for either risk score, analysis of the highest bin with gout cases gave OR = 9.4 [3.8; 23.3] and OR = 6.2 [2.3; 17.0] for European and trans-ancestry risk scores, respectively.

Equivalent risk scores were generated using SNPs from the European and trans-ancestry male-only and female-only GWAS. The 246-SNP risk score derived from the male-only European GWAS had a higher prevalence of gout (50.0%) and higher risk of gout (OR = 36.4 [2.2; 609.3]) in the highest risk score bin than the highest risk score bin generated from the full (sexes combined) European GWAS SNPs (**Figure S5**). The 265-SNP risk score derived from the male-only trans-ancestry GWAS did not improve upon the full trans-ancestry risk score in the highest risk score bin (gout prevalence 26.9%; OR = 15.1 [6.2; 36.3]). Both the European and trans-ancestry female-only risk scores had higher gout prevalence (5.3% and 3.8%) and OR (12.6 [3.0; 53.6] and 12.4 [3.8; 40.1]), respectively, in the highest bin than the risk score derived from the respective full (sexes combined) GWAS (**Figure S4**).

The 289-SNP European gout risk score improved gout risk prediction in Europeans (area under the receiver operating characteristic curve (AUROC) estimate of 0.71), compared to a 114-SNP risk score generated from a serum urate GWAS in European individuals⁹ (AUROC estimate of 0.66) (**Figure S6; Table S5**). These estimates were the same in the male-only AUROC estimates, and lower in the female-only estimates (0.68 for the gout risk score and 0.62 for the urate-derived risk score). Adding age increased the prediction accuracy of the gout risk score to 0.73 in males and 0.74 in females.

Genetic relationships with other phenotypes

To investigate the genetic correlation between gout and other complex phenotypes, LD score regression was undertaken using 934 traits reported in the UK Biobank, the European gout GWAS data and, for comparison, data generated from a GWAS of serum urate in European UK Biobank participants without gout (**Methods**). There was significant genetic correlation between gout and 348 phenotypes, which spanned 25 out of 27 broad phenotype categories (**Figure 3, Figure S7, Table S6**). As expected, the strongest correlations were with gout and urate ($r_g \geq 0.89$). Outside of cardiovascular disease and its body composition-related risk factors, established as associated with gout, negative correlations were seen with two sex-related blood biomarkers, testosterone ($r_g = -0.17$) and sex hormone-binding globulin ($r_g = -0.31$). This is consistent with a recent report of greater genetically predicted levels of each hormone associating with reduced risk of gout³². There was positive genetic correlation between gout and blood counts of leukocytes, lymphocytes, neutrophils, eosinophils, and reticulocytes ($r_g = 0.17, 0.14, 0.15, 0.12, \text{ and } 0.26$, respectively). Finally, positive genetic correlations between gout and various measures of negative mood were observed. The

genetic correlations with urate levels were very similar (**Figure 3**) with 300 of the 348 phenotypes correlated with gout also significantly correlated with urate in the UK Biobank in a consistent direction.

To investigate the possibility of testing for causality of gout for the 348 phenotypes correlated with gout, we tested the 289 SNPs that were included in the European gout polygenic risk score (above) for evidence of vertical pleiotropy with the 348 phenotypes using two-sample Mendelian randomization (MR) in MRBase by the MR-Egger (Egger intercept) approach. There was extensive pleiotropy, with 69 phenotypes having evidence of pleiotropy at a Bonferroni-corrected level of significance ($0.05/348 = 1.4 \times 10^{-4}$), 93 with $P < 0.001$, and 146 with $P < 0.01$, which would complicate interpretation of any causal relationships identified via Mendelian randomization (**Table S7**). In the absence of a clear understanding of the molecular mechanisms of the genetic variants comprising the genetic instrument, further Mendelian randomization analysis was not pursued.

Candidate Variants, Genes, and Tissues

Tissues enriched in gout

We analyzed the summary statistics of the four ancestries (African, East Asian, European, and Latinx) for significantly enriched tissues / cell-type groups and specific cell-types using covariate-adjusted LD score regression (cov-LDSC; Methods)³³. In East Asian there was evidence of significant enrichment of tissues (Bonferroni-corrected $P_{\text{coef}} \leq 0.05/40$) in kidney (10.8-fold enrichment; $P_{\text{coef}} = 2.3 \times 10^{-4}$), and in European there was enrichment in the kidney and liver (11.6-fold enrichment; $P_{\text{coef}} = 8.6 \times 10^{-7}$ and 5.1-fold enrichment; $P_{\text{coef}} = 8.3 \times 10^{-6}$, respectively) (**Table S8; Figure S8**). There were no significant enrichments observed in

either of the African and Latinx analyses. With respect to which specific cell-types were significant in European, we observed significant cell-type associations (false discovery rate (FDR) ≤ 0.05) in small and large intestine, colonic mucosa, duodenum mucosa, rectal mucosa, pancreas, skeletal muscle, kidney, and liver (**Table S9; Figure S9**). There were three significant kidney cell histone marks found in the East Asian cell-type analysis (H3K4me3, H3K9ac, and H3K27ac) that were also identified in the European ancestry analysis (**Table S9**).

Cis- and trans-eQTL co-localization analyses

To identify candidate causal genes that are possibly controlled through regulation of gene expression, we focused on gout association signals that co-localized with *cis*- and *trans*-eQTL across 49 tissues in the Genotype Tissue Expression (GTEx) database. Of the 342 trans-ancestry and European lead SNPs present in GTEx (or its proxy if the lead variant was not present), 290 (84.8%) had at least one co-localized eQTL (posterior probability of co-localization (PPC) ≥ 0.5) representing 890 genes. There were 2,717 *cis*-eQTL over multiple tissues for 626 genes and 332 *trans*-eQTL (31 were both *cis*- and *trans*-eQTLs) over multiple tissues for 326 genes with evidence of co-localization (**Table S10; Figure S10**).

Of the 921 eQTL implicated by co-localization analysis, ten had control of expression by both a *cis*- and *trans*-eQTL (*ADK*, *HSP90AA1*, *RABEP2*, *SEPT9*, *SPN1*, *VPS9D1*, *RNF157*, *SLC16A9*, *TANCI* and *TUBB8P7*). For example, *rs1171614* is the lead SNP for a co-localized *cis*-eQTL for *SLC16A9* (encodes kidney monocarboxylate transporter SLC16A9 involved in carnitine transport) and *SLC16A9* is a *trans*-eQTL of *rs73592376* at the *CUBN* (proximal tubule uptake receptor) locus. We also noted that 47 of the 343 eQTL that had an

eQTL in multiple tissues had opposing effects on gene expression between tissues (**Table S11**). Focusing on genes that may have a role in gout inflammation there were 11 genes with eQTLs in whole blood, of these genes five (*AQP10*, *BAG4*, *FADS1*, *SCAP*, *RP11-936I5.1*) had a direction of effect opposite to all other tissues in which an eQTL was observed.

Only five co-localized kidney cortex eQTL were observed in GTEx (*FGF5*, *HLF*, *ITIH4*, *RP11-307C18.1*, *NUDT2*), therefore we also leveraged comprehensive kidney eQTL data from the Susztaklab Kidney Biobank³⁴ to identify additional kidney eQTL. We used LD ($r^2 > 0.8$) between the lead gout and the lead kidney eQTL SNPs to identify 137 genes with gout-associated kidney eQTL, 69 of which also had a co-localized eQTL identified in other tissues within the GTEx data (**Table S12**).

We used Activity-By-Contact (ABC) data³⁵ to determine if the lead signals with co-localized eQTL showed evidence of gene regulation through enhancers. Of the 290 lead variants that had signals co-localized with *cis*- and/or *trans*-eQTL, 55 variants were within an ABC enhancer for 386 genes with ABC-score ≥ 0.015 (**Table S13**). 31 of these 55 variants were within an activity-by-contact enhancer for 48 co-localized eQTL (all in *cis*; **Table S14**), indicating that these variants may be altering gene expression by directly affecting the functional interaction between the putative enhancer and gene promoter.

Tissue-specific eQTLs

Reasoning that co-localized eQTL restricted to a single GTEx-defined tissue may be more tractable to specific biological insights than those expressed in multiple tissues, we filtered for tissue-specific co-localized eQTL (**Table S15**), identifying 581 eQTL genes. Of specific

interest are the eQTL in the testis for *SLC34A1*, *HNF4G*, and *PRPS2* – genes with known roles in urate transport, production, and homeostasis – suggesting that the function of these genes in urate control could have male-specific mechanisms. Additionally, the co-localized eQTL for *XDH* (encoding xanthine oxidoreductase (XOR)) was specific to the prostate. In female-specific tissues (ovary, vagina and uterus), we identified *COG5*, *JAZF1-AS1*, *FDX1P1*, *SPDYE18*, and *SDK1*, none of which play known roles in urate homeostasis or gout risk. We identified only two co-localized eQTLs specific to kidney tissue in GTEx (*FGF5* and *ITIH4*), and an additional 68 kidney eQTL from the Susztaklab Kidney Biobank³⁴ not present in GTEx. Notable amongst the 68 was *SLC22A12* (encodes canonical urate transporter URAT1³⁶) that has not previously been demonstrated to have gout-associated genetic control of expression in the kidney. We found seven liver-specific (*BSN*, *KLB*, *STK19B*, *TNKS*, *RAI1*, *ZDHHC14*, and *ZNF320*) and 16 whole blood-specific (*DGAT2*, *RPS6KB1*, *MBD5*, *C5orf42*, *MAP2K1*, *CDKL5*, *ARID4B*, *CARS*, *CSNK1G1*, *AUH*, *HEATR5B*, *AF064858.8*, *IL27*, *HAUS1P1*, *ZNF675* and *DPEP3*) co-localized eQTL.

DNA Methylation QTL co-localization analysis

The epigenetic reprogramming (‘trained immunity’) of monocytes by elevated levels of soluble urate is implicated in the etiology of gout^{7,37,38}. To evaluate the possibility that gout-associated loci also associated with control of DNA methylation status in the blood, we conducted co-localization analysis between whole blood DNA methylation QTL (meQTL) in the GoDMC data set³⁹ derived from European participants, using the 291 lead SNPs in the European GWAS. We identified 520 methylation CpG sites within 1Mb of a lead gout-associated SNP that also co-localized with a European GWAS signal (**Table S16**; PPC ≥ 0.8 and ≥ 100 variants in the 1Mb segment used for co-localization). To determine whether the

implicated 520 CpG sites were involved in transcriptional regulation, we tested for enrichment in protein-binding within ± 50 base pairs of the CpG sites using merged ChIP-seq data for 338 DNA-binding proteins from 1,536 cell-lines⁴⁰. Significant enrichment was observed for 27 DNA-binding proteins (Bonferroni-corrected Fisher's exact $P \leq 1.48 \times 10^{-4}$) (**Table S17**) that bind to a total of 499 (96.0%) co-localized meQTL CpG sites (median = 54 CpG sites, mean = 76.9 CpG sites). Of the 27 DNA-binding proteins identified, only one was within a gout genetic association signal (*IRF1*). Amongst the top enriched DNA-binding proteins were the histone acetylation writers and readers EP300 and BRD4. BRD4 has previously been implicated in the regulation of the NLRP3 inflammasome through regulation of NF κ B signalling,⁴¹ BRD4 inhibition ameliorates urate crystal-induced gouty arthritis by regulation of pyroptosis in a rat model^{42, 43}.

The kidney is a key organ in urate homeostasis. Given that variation in DNA methylation in the kidney mediates 46% of heritability in kidney function traits⁴⁴, we also identified 328 genetic variants that were kidney meQTL for 576 CpG sites in strong LD ($r^2 \geq 0.8$) with a gout genetic association using the Liu *et al.*⁴⁴ dataset (**Table S18**). The 50 kidney eQTL that also had at least one kidney meQTL were enriched for transcription factor binding of HNF4G using the enrichr gene set search engine⁴⁵ ($P = 0.03$). For each of the kidney eQTL with co-localized meQTL we looked for SNPs in linkage disequilibrium ($r^2 \geq 0.8$) with the lead gout SNPs that overlap a transcription factor binding site for HNF4G using HaploReg. We found three variants that overlap and disrupt a matching HNF4A/G motif: *rs2453583* at *SLC47A1*, *rs1165183* at *H2BC1* (at the *SLC17A1-4* locus) and *rs260512* at *SKI*. Regulatory control of *SKI* and *H2BC1* has not previously been associated with gout or serum urate.

Fine-mapping of loci

We used three approaches (Bayes factor, FINEMAP⁴⁶, and PAINTOR⁴⁷) for fine-mapping the 376 unique loci in the European and trans-ancestry datasets from all analyses (full, male-only, and female-only). We considered 99% credible sets from any one of the separate approaches with at least one variant with posterior inclusion probability (PIP) ≥ 0.5 . Between the three fine-mapping approaches and cohorts, we found a credible set with at least one variant with PIP ≥ 0.5 in 285 loci (76.6%) (**Table S19**). The fine-mapping of complex phenotype loci is compromised when summary statistics derived from meta-analysis of cohorts using different genotyping arrays and/or imputation panels are used. Therefore, we first identified and excluded compromised loci using SLALOM⁴⁸. Of the 285 loci, 70 loci (24.6%) in total were flagged as compromised by SLALOM in at least one of the cohorts (**Table S20**). 215 loci remained after removing the compromised loci from the relevant cohort (**Table S21**) and 608 candidate causal SNPs (PIP ≥ 0.5 in one or more of the fine-mapping approaches and within a 99% credible set with ≤ 5 SNPs) were selected for further analysis (**Table S22**). Of these 608 variants, 37 were identified by two fine-mapping approaches and 16 were identified by all three approaches. We created a pool of 1,466 unique candidate causal variants (**Table S24**) from; a) the 799 lead SNPs from single- and trans-ancestry GWAS in all cohorts (254/799 = 31.8% present in the fine-mapping credible set results); b) from an additional 185 variants identified as conditionally associated with gout after applying GCTA-COJO⁴⁹ to the European GWAS data (Methods; **Table S23**) (26/185 = 14.1% present in the fine-mapping credible sets); and c) the 608 variants identified by fine-mapping (**Table S22**) (there were 126 variants common to the three categories). The 1,466 SNPs in this pooled list were then assessed for their potential to disrupt gene function.

Candidate causal missense variants

Of the 1,466 SNPs in the pooled list, there were 21 missense variants. There were an additional 173 missense variants that were in strong LD with the 1,466 candidate variants ($r^2 > 0.8$ in any of the relevant ancestries from 1000 Genomes) (**Table S25**). In addition to the genes with the 21 missense variants there were 26 other genes with a missense variant that was a lead SNP in one of the GWAS (including lead SNPs identified by conditional analysis) or had LD of $r^2 \geq 0.98$ with a lead SNP (**Table 1**). Of the combined 47 genes there were 16 with missense variants with information on protein function impact that supports causality, including 7 not previously reported as genetically or functionally implicated in serum urate control or gout (*ABCA6* p.Cys1359Arg, *GLS2* p.Leu581Pro, *MC4R* p.Val103Ile, *PNPLA3* p.Ile148Met, *SH2B3* p.Trp262Arg, *SLC39A8* p.Ala391Thr, *SLCO1B1* p.Val174Ala). Two of the genes with missense variants associated with serum levels of amino acids (*CPS1* and *GLS2*), and the *CUBN* and *LRP2* genes (encoding cubilin and megalin, respectively) physically interact in the kidney proximal tubule to resorb proteins from filtered urine⁵⁰.

Candidate causal non-coding variants

To further investigate the remaining 1,445 non-coding candidate causal variants, we used the FATHMM⁵¹ non-coding score to determine if the SNP was predicted to be deleterious, and overlapped with activity-by-contact enhancer regions to determine if the variant mapped within an enhancer region that contacts a gene promoter³⁵. Ninety-nine variants (7.0%) were predicted to be deleterious based on the FATHMM score for non-coding variants (FATHMM score ≥ 0.5), 256 variants (18.0%) were within an ABC-predicted enhancer for at least one gene (ABC-score ≥ 0.015), and 32 SNPs had a high FATHMM score and were also within an ABC enhancer that mapped to 78 genes (**Figure S11, Table S26**). Of these 32 SNPs, 29

overlapped enhancer marks and/or DNase hypersensitivity regions in blood, and ten had a co-localized eQTL for the gene(s) with which they physically interacted through an ABC enhancer (**Table S27**). Of the ten only two had eQTL in whole blood: *rs2439303* (*NRG1*) and *rs2645479* (*RPS6KB1*).

Investigation of underlying function

Pathway analysis

To gain insights into biologic mechanisms we carried out pathway and gene ontology (GO) analyses using the 1,768 genes (**Table S28**) from the combination of missense genes with candidate casual missense variants (**Table 1**), co-localized eQTL genes, and the significant MAGMA genes (**Table S29**). These analyses were significantly enriched for the GO term urate metabolism, REACTOME pathways Chromatin Organization and Chromatin Modifying Enzymes, and the KEGG pathways Type II Diabetes Mellitus and PI3K-Akt signalling pathway (**Figure 4**). The 46 genes that contribute to both the REACTOME Chromatin Organization and Chromatin Modifying Enzymes terms included histone methyltransferases *EZH2*, *KMT2A*, *SETD1A*, *SETD2*, and three lysine demethylases *KDM3A*, *KDM4C*, and *KDM6B*. The 15 genes that contribute to the KEGG Type II Diabetes Mellitus and the 59 genes that contribute to the PI3K-Akt signalling pathways, include the insulin receptor (*INSR*), insulin substrate receptor 1 (*IRS1*), insulin growth factor 1 receptor (*IGF1R*), NFκB subunit *RELA*, p70S6 kinase (*RPS6KB1*), and *PIK3CB*.

Prioritization of genes predicted to control gout inflammation

To identify candidate causal genes for follow-up that are more likely to be involved in the progression from hyperuricemia to gout, we developed a set of gene-centric criteria

(**Methods**) that we applied to 5,014 unique genes within the boundaries of all identified GWAS loci and an additional 412 *cis*- and *trans*-eQTL genes outside the boundaries (**Table S30**). Following application of the gene-based criteria to the 5,426 genes we sub-ranked the genes within each score by function-agnostic criteria: 1) gene with closest transcription start site; 2) implicated by activity-by-contact; and 3) containing a strong candidate missense causal variant (**Table 1**). This prioritization scheme revealed strong candidate genes for a role in the initiation and resolution of the gout flare (**Figure 5**). We found 117 genes with prioritization scores between four and seven, with transcription start sites closest to the lead gout-associated SNP and/or evidence from activity-by-contact for regulation of expression by an enhancer. This prioritization evidence strongly warrants follow-up analyses in these 117 genes. Among these genes are *FADS1*, *DGAT2*, and the highest scoring gene *FADS2*, that are all involved in lipid metabolism, and *IRF5*, *IL1R1*, *TRAF4*, *IL6R*, *IK*, and *MAST3* all implicated in the inflammatory response. To support our prioritization approach, we identified category enrichments using DAVID⁵² for the gene-disease association dataset class category ‘Immune’ ($P = 2.9 \times 10^{-11}$) and the transcription factor NF κ B ($P = 3.8 \times 10^{-17}$) for 585 genes scored ≥ 3 in the prioritization scoring (**Table S31**). These enrichments were maintained in the 519 genes that remained when we excluded the 66 genes at the HLA locus ($P = 1.3 \times 10^{-3}$ and 2.5×10^{-15} , respectively; **Table S32**).

The IL1RN locus and IL-1 β response to monosodium urate crystal stimulation

The Human Functional Genomics Project (500FG) is a repository of cytokine QTL (cQTL) data, including data on association between IL-1 β and IL-6 response to monosodium urate crystal/C16 stimulation in peripheral blood mononuclear cells⁵³. We investigated the associations between the 500FG IL-1 β or IL-6 response to stimulation and 41 lead SNPs

from the European or trans-ancestry GWAS that were not associated with urate in the UK Biobank (**Methods**) and had genotype data available in the 500FG dataset (either the variant itself or a proxy; $r^2 \geq 0.8$) and of 202 lead variants associated with urate. There was evidence of amplification of association signals in the 41 non-urate-associated SNPs for IL-1 β response, but not in the 202 urate-associated SNPs (**Figure S12, S13**). The lead SNP at the *IL1RN* locus was the only SNP significantly associated with IL-1 β response to monosodium urate crystal stimulation (*rs9973741*; risk-allele (G) $\beta = 0.34$, $P = 3.6 \times 10^{-4} < 0.05/41$). IL-6 response to monosodium urate crystal/C16 stimulation also associated with *rs9973741* ($\beta = 0.32$, $P = 2.4 \times 10^{-4}$). This SNP did not associate with either response upon stimulation by *C. albicans* ($\beta = 0.04$, $P = 0.20$ and $\beta = -0.07$, $P = 0.19$, respectively).

Association signals at this locus co-localized between gout and genetic control of *IL1RN* expression in testis and sub-cutaneous adipose tissues, and *IL1F10* (*IL-38*) expression in skin (**Figure S14**). The G-allele associated with increased expression of *IL1RN* in the testis and skin ($\beta = 0.29$, $P = 4.0 \times 10^{-11}$; $\beta = 0.13$, $P = 1.7 \times 10^{-8}$) and reduced expression in sub-cutaneous adipose ($\beta = -0.13$, $P = 2.0 \times 10^{-5}$), and with reduced expression of *IL1F10* in the skin ($\beta = -0.18$, $P = 1.1 \times 10^{-9}$). Collectively, these findings are consistent with the hypothesis that the genetic influence on the risk of gout occurs through control of IL-1 β production by the innate immune system when activated by MSU crystals, contributing to the control of *IL1RN* and/or *IL1F10* gene expression.

Xanthine oxidoreductase

Xanthine oxidoreductase (XOR), the sole enzymatic source of urate that oxidizes hypoxanthine to xanthine and then xanthine to urate, is a key gout intervention point with

urate-lowering therapy. XOR is transcribed and translated as xanthine dehydrogenase (XDH), with the circulating form exhibiting dehydrogenase and oxidase activity. Given the key role of XOR in the pathogenesis of gout and evidence for association of a burden of rare variants in *XDH* with reduced urate level⁵⁴, we explored the significant association of the *XDH* locus with gout in more depth. There were clear signals of association with urate in the independent UK Biobank (**Methods**) and Tin et al.⁹ studies that overlapped the gout signal (**Figure 6**), with the gout risk allele in strong LD with the urate-increasing allele in each of the urate datasets. At the *XDH* locus we identified a *cis*-eQTL for *XDH* that was specific to the prostate (**Table S15**). The gout risk allele associated with increased *XDH* expression in the prostate. There were eQTL for *XDH* in other tissues (the notable exception being the liver) but none co-localized with the gout genetic association signal (**Figure 6**). Sex-stratified analysis of the gout GWAS data provided evidence for an association signal in men but not in women (**Figure 6**; *rs7594951* C-allele $OR_{\text{female}} = 1.02$ [95% CI; 0.99-1.05], $OR_{\text{male}} = 1.05$ [95% CI; 1.03-1.08]).

The presence of urate in seminal fluid,⁵⁵ urate crystals in 19/40 (47.5%) of non-malignant prostate sections,⁵⁶ and the expression of *XDH* in the prostate (gtex.org) suggests that the prostate synthesizes urate. Supporting this we demonstrated Xor activity and urate content in the prostate of 7-week-old C57Bl/6 mice, with the urate concentration equivalent (per mg of protein) to that in liver (**Figure 6**). Our genetic data in humans implicate shared genetic control of prostate *XDH* expression and the risk of gout in men, suggesting that the prostate may secrete urate into the blood. Investigating this possibility further, we first assessed expression of urate transporters in GTEx data. Three genes encoding urate transporters were expressed: *ABCC4* (median transcripts per million (TPM) of 1.73, tissue with second highest

expression after bladder); *ABCG2* (TPM of 7.6, widely expressed); and *SLC2A9* (TPM of 3.5, tissue with 4th highest expression after kidney, esophageal mucosa, bladder). There was negligible expression of *SLC22A6-A8*, *SLC22A11/A12*, and *SLC17A1-A4*. Analysis of prostate single-cell RNA expression data showed that the expression of both *XDH* and *SLC2A9* occurs in basal epithelial cells, *ABCC4* is expressed in basal and luminal epithelial cells and the expression of *ABCG2* is restricted to endothelial cells (**Figure 6**).

Clonal hematopoiesis of indeterminate potential (CHIP)

CHIP is defined as the presence of clonally expanded cells with somatic mutations in an individual with no evidence of hematologic malignancy. Mutations are present in a suite of 71 genes, most prominently in genes that encode epigenetic modifiers. Recently CHIP has been associated with incident⁵⁷ and prevalent gout⁵⁸ but not urate⁵⁷ and has been hypothesized to play a role in epigenetic reprogramming of the innate immune system to be more responsive to stimulation by monosodium urate crystals⁵⁹. Given also that our pathway analysis also revealed chromatin modification to be a significant enrichment term, we investigated if germline genetic variation in the loci harbouring the 71 CHIP genes could play a role in gout. Nineteen of the 71 genes (**Table S33**) were present in the 2,598 protein-coding genes (out of a total of 21,474 from GenCode) within the boundaries of all identified gout-associated loci, a significant over-representation ($P = 0.0002$), consistent with the hypothesis that the CHIP pathway plays a causal role in gout. Enabled by a GWAS for CHIP risk alleles,⁵⁷ we performed two-sample Mendelian randomization to test for a causal relationship of the CHIP phenomenon for gout (**Figure 7; Table S34**). There was evidence for a positive causal role of *DNMT3A*-CHIP in gout (weighted median MR estimate 0.034, $P = 0.003$; inverse variance weighted MR estimate 0.061, $P < 0.001$) but not for CHIP *per se* or *TET2*-

CHIP. For the *DNMT3A*-CHIP analysis, there was no suggestion of horizontal pleiotropy by MR-EGGER (intercept 0.013, $P = 0.23$; **Table S34**).

Loci with cis-eQTL for protein-coding and lncRNA genes – candidate immune-priming lncRNAs

Of the lead variants, 212 were a *cis*-eQTL for a protein-coding gene, of which 75 (35.3%) also had a *cis*-eQTL for a long non-coding (lnc) RNA. The lncRNAs at these 75 loci are candidate immune-priming lncRNAs (IPLs) that may prime immune genes for robust transcription by facilitating transcriptional machinery assembly (e.g. the prototypical UMLILO lncRNA⁶⁰), and can be regarded as potential targets for RNA-mediated therapeutics. Indeed, two gout associated loci containing *CSF1* and *IRF1* were previously identified as being connected by a IPL⁶⁰. To identify candidate IPLs amenable for follow-up mechanistic study, we prioritized the 75 loci based on the protein-coding gene having an eQTL in whole blood, and a high prioritization score (**Table S30**) for a role in the progression from hyperuricemia to gout (**Table 2**). We also included in this set the lncRNA DRAIR, previously functionally implicated in the immune response of macrophages⁶¹. Two of the eQTL-lncRNA pairs both had an eQTL in whole blood (*DGAT2/RP11-535A19.2* and *BAG4/RP11-350N15.5*).

We used GeneHancer to examine evidence of physical connections between the lead genetic variants, the lncRNA and the protein-coding gene at *DGAT2* (**Figure 8**) and other genes in **Table 2** (**Figure S15**). We identified physical connections between the lncRNA and the protein-coding genes at *DGAT2* and other loci. Of particular interest is the highly prioritized gene *DGAT2* (**Figure 5**). The gout risk allele associates with decreased *DGAT2* and *RP11-*

535A19.2 expression. The promoters of *DGAT2*, *RP11-535A19.2* and *UVRAG* are marked by H3K4me3 (**Figure 8**). There are also six CpG sites at *DGAT2* with co-localized meQTL. The gout risk allele associates with increased CpG methylation at all sites except cg02337499, which is found at the promoter of *UVRAG*. A GeneHancer physical connection was observed between a maximally associated variant *rs11236533*, the lncRNA and *DGAT2*. Functional data for *rs11236533* indicates that it is bound by CTCF (a CHIP gene which also maps to a male-only gout-associated locus) in numerous cell types including monocytes and neutrophils and is predicted to alter a CTCF motif. *Rs11236533* physically connects to *DGAT2* via two GeneHancer regions containing additional maximally associated variants (region 1: *rs7947512*, *rs10899119*, *rs11823869* and *rs10219339*; and region 2: *rs11236530*). In the ImmuNeXUT dataset⁶², *rs11236533* is the lead variant for an eQTL for *DGAT2* and *CTD-2530H12.2* in neutrophils and the gout risk allele decreases expression of both genes in blood. Collectively these data suggest the possibility that this region is under immune cell-specific regulatory control that may be mediated by DNA methylation and the expression of lncRNA *RP11-535A19.2* at this locus.

Drug targets

We took a systematic approach to identifying drug targets using the Genome for Repositioning (GREP) drugs pipeline. We used MAGMA²⁸ (for generalized gene set analysis of GWAS data) on the combined trans-ancestry meta-analysis to identify 476 genes (**Table S35**) for input into GREP (**Figure S16**)⁶³, which examines a gene set for enrichment in drug targets by clinical indication category (Anatomical Therapeutic Chemical Classification System (ATC) or International Classification of Diseases 10 (ICD10) diagnostic code). In the ATC analysis the only category nominally significant was ‘antigout preparations’, driven by

target genes *SLC22A12* (encoding URAT1) and *SLC22A11* (encoding OAT4) and uricosuric drugs lesinurad, sulfinpyrazone and probenecid. Xanthine oxidase inhibitors were excluded because the *XDH* gene was not significant ($P=1.0$) in the MAGMA analysis and was not included in the input gene list. In the ICD10 analysis nominally significant categories were neoplasms, blood biochemistry and metabolic disorders, driven by the *CASP9*, *CCND1*, *CHEK2*, *DRD5*, *IGF1R*, *INSR*, *PPARG* and *DGAT2* genes. The ICD10 M5-M14 ‘inflammatory polyarthropathies’ category that includes gout was not significant ($P = 0.16$), nor was ICD10 M10 gout code ($P=0.59$).

Discussion

The sample size of this trans-ancestry gout GWAS (2.6M individuals) represents a 3.2-fold increase in people with gout over the previous largest study, the Global Biobank Meta-analysis Initiative that detected 52 loci¹⁶. The increase in sample size allowed a substantial increase in detected loci, to 376 in total (of which 148 were new in urate and gout), facilitating new findings into the molecular pathogenesis of gout. Study size allowed us to perform sex-specific GWAS and to discover 39 loci not detected in the main analysis. We present evidence for genetic control of expression of *XDH* that co-localizes with genetic association with gout and urate levels only in the prostate, implicating the prostate in urate homeostasis, and we provide evidence for a causal role of clonal hematopoiesis of indeterminate potential in gout. Top pathways identified are synthesized into **Figure 9**. Given previous major insights into the molecular control of urate levels by GWAS^{9,25,64,65}, we focused this study on identifying molecular mechanisms of the progression from hyperuricemia to symptomatic gout for which we generated a comprehensive list of target genes for follow-up studies.

Co-localization of the male gout genetic association signal at *XDH*, with genetic control of *XDH* expression only in the prostate, with the gout-risk allele associated with increased prostate expression of *XDH*, generates the hypothesis that the human prostate synthesizes urate, contributing to increased urate levels and higher risk of gout in men. The relative contribution of different tissues to circulating urate in humans is not quantified, although the liver is a substantial contributor (in mouse, ~50% of plasma urate is contributed by the liver⁶⁶ with relative contributions of other murine tissues unknown). Urate is a constituent of human semen^{55,67} and MSU crystals were present in 19 of 40 (47.5%) non-malignant prostate

sections⁵⁶, suggesting that it is common to have urate super-saturation in the prostate. The supposition that the prostate exhibits XOR activity is supported by demonstration of XOR activity and urate content in the prostate of C57Bl/J6 mice with the prostate urate concentration equivalent to the liver (**Figure 6**). *XDH*, *SLC2A9* and *ABCC4* are co-expressed in the urothelial cells, and the gene encoding the urate secretory transporter *ABCG2* is predominantly expressed in the endothelial cells of the human prostate. This is consistent with a model of urate reuptake by GLUT9 (encoded by *SLC2A9*) from the urethra by urothelial cells, and urate synthesis in epithelial cells by XOR. Urate could then be transported out of epithelial cells by GLUT9 and/or *ABCC4* and transported from endothelial cells into the circulation by *ABCG2*.

From the full GWAS, 36 loci had effect sizes that differed between sexes, all with a stronger effect size in men. These are dominated by previously urate-associated loci. This is consistent with the emerging consensus that urate control and subsequent risk of gout has a stronger genetic component in men (e.g. contributing to lower fractional excretion of urate in men⁶⁸), whereas in women, who develop gout at an older age, increased urate levels are driven by a higher burden of comorbidity^{27,69,70}. Excepting the African analysis, *ABCG2* consistently exhibited heterogeneity with a stronger effect size in men, consistent with the heterogeneity observed in association with urate⁹. In contrast, *SLC2A9* has a stronger urate effect size in women⁹, but a stronger gout effect size in men, as did *AICF* and *IGFRI*. The reason for this is unclear, but it may reflect an additional role of the loci in the progression from hyperuricemia to clinical gout. Considering *SLC2A9* and *IGFRI*, in the context of urate control, there is a differential effect of *IGFRI* genotype on urate levels between men and

women in the presence of the urate-lowering genotype at *SLC2A9*. Functionally, IGF1 stimulates urate reuptake by GLUT9 (encoded by *SLC2A9*) via IGFR1⁷¹.

We developed an approach to prioritize from the gene pool encompassed by the 376 loci genes for follow-up, predicted to control the innate immune response to MSU crystals. Our primary prioritization scheme focused, by necessity, on the gene *per se*, and did not incorporate aspects of previously proposed functionally-agnostic variant-to-gene criteria^{72,73}. However, we secondarily ranked on some genomic criteria which serves to increase confidence in causal candidacy. This analysis identified several notable genes that illuminate new pathways in gout. The top-ranked gene (out of 5426) was *FADS2*, with *FADS1* ranked 13th. These genes, adjacent on chromosome 11, encode fatty-acid desaturases involved in the synthesis of unsaturated omega-3 fatty acids that inhibit NLRP3 inflammasome activation⁷⁴. Increased *FADS2* expression correlates with reduced circulating arachidonic acid and increased circulating IL-1 β , TNF- α , and IL-6 levels⁷⁵. Furthermore *FADS2*-knockdown reduced innate immune response to *C. albicans* and *FADS2* inhibition reduces proliferation of innate immune cells^{75,76}. Consistent with a role for *FADS2* in gout, the risk allele (*rs61897795* G-allele) associates with increased expression of *FADS2* in blood. The genes encoding interleukin-1 receptor 1 (*IL1R1*) and interleukin-6 receptor (*IL6R*) were ranked 15th and 47th, respectively. They both are co-localized eQTL in monocytes, are differentially expressed in monocytes exposed to lipopolysaccharide or monosodium urate crystals⁴³, their TSSs are contacted by an enhancer, and they have the closest TSS to the lead gout-associated genetic variant. IL-1R1 is antagonized by anakinra, which is an effective option for treatment of gout flares⁷⁷. Interestingly the *IL-1R1* genetic signal, along with an intergenic signal on Chr21:40.4 - 40.5Mb (*rs4817983*, *rs2836884*), are the only signals to be present in both the

European and trans-ancestry analyses (including sex-specific) and which have not been previously reported in gout or urate related GWAS. The Chr20 locus has been found to associate with white blood cell traits^{78,79} and other inflammatory conditions including ulcerative colitis⁷⁹ and Takayasu's arteritis⁸⁰. Interleukin-6 is secreted by monosodium urate crystal/lipopolysaccharide-activated monocytes⁸¹. Although neither IL-6 nor IL-6R have been rigorously evaluated as targets in the management of gout, the JAK-inhibitor baricitinib, one effect of which is to block IL-6R signalling, reduces IL-1 β secretion in the response of IL-6-primed neutrophils to monosodium^{82,83}, and case reports indicate efficacy for the IL-6R antagonist tocilizumab in refractory gout⁸³⁻⁸⁵.

We identified 47 genes with candidate causal missense variants. *AQP10*, encoding aquaporin 10, ranked 296th in our prioritization scheme and is a co-localized eQTL in whole blood, however the lead associated variant is also in strong linkage disequilibrium ($r^2 \geq 0.98$) with two missense variants (*rs6668968/p.Arg15Gln* and *rs6685323/p.His123Tyr*). Aquaporins allow small solutes (e.g. water, glycerol) to cross membranes. *AQP10* has low levels of expression in most tissues, with higher expression in whole blood, fallopian tube, lung, spleen and testis, and transports water in a pH-independent manner and glycerol in a pH-dependent manner, playing a role in lipolysis in adipocytes⁸⁶. The regulation of cell volume induces ionic changes that regulate NLRP3 inflammasome activation⁸⁷ and monosodium urate crystal-induced production of IL-1 β by THP-1 monocytes is reduced with inhibition of aquaporins⁸⁸, suggesting cellular osmolarity to be a newly implicated causal mechanism in gout. The *CUBN* and *LRP2* genes encode cubilin and megalin, large endocytic proteins expressed in the kidney proximal tubule that resorb protein from the urine. Both genes also associate with urate levels and the combined activity of cubilin and megalin may influence

urate levels and the risk of gout through an influence on filtration of urate by the kidney. Interestingly, the *CUBN* locus controls expression of *SLC16A9* in *trans* – the *SLC16A9* locus itself associates with urate, gout and carnitine levels⁸⁹ and *SLC16A9* encodes a creatine transporter in the kidney proximal tubule. *SLC5A1* encodes sodium-glucose transporter 1 (SGLT1) and is primarily expressed in the small intestine. Recently, in the context of the established urate-lowering effect of SGLT2 inhibitors⁹⁰ (SGLT2 is expressed primarily in the kidney), Mendelian randomization using the *rs17683430* (p.Ala411Thr) variant supported SGLT1 inhibition as a therapeutic option in gout⁹¹. Two mitochondrial enzymes *CPS1* encoding carbamoyl phosphate synthase 1 and *GLS2* encoding glutaminase 2 have candidate missense variants, with the gout risk allele of *CPS1* associated with lower arginine levels⁹² and the gout risk allele of *GLS2* associates with reduced glutamine levels⁹³. The missense variants may impact Krebs cycle metabolites and possibly contribute to gout risk via immunometabolic epigenetic reprogramming through histone modifications⁹⁴.

Clonal hematopoiesis of indeterminate potential (CHIP) occurs as a result of white blood cell somatic mutation in a suite of genes, predominantly in *TET2* and *DNMT3A*. Consistent with a previous report of association of CHIP with gout⁵⁸ we observed an over-representation of genes mutated in CHIP mapping to gout loci. By Mendelian randomization, using instruments comprised of genetic variants associated with CHIP *per se*, *TET2*-CHIP and *DNMT3A*-CHIP, we provided evidence for a causal role of CHIP for gout, implicating CHIP (specifically *DNMT3A*-CHIP) as a causal pathway in the pathogenesis of gout. Genes mutated in CHIP and associated with gout include epigenetic regulators (e.g. *TET2*, *EZH2*), damage response proteins (e.g. *PPM1D*) and metabolic enzymes (e.g. *IDH2*). *TET2*, *EZH2* and *IDH2* are all strong candidate genes for gout, being eQTL that co-localize with gout-

associated GWAS signals. *IDH2*, encoding isocitrate dehydrogenase 2, produces α -ketoglutarate in the Krebs cycle, a source of substrates for epigenomic modification and also a co-factor for histone demethylases and the TET family of demethylases⁹⁵. It is unclear how CHIP *per se* could cause gout. However, somatic mutation in CHIP genes associated with gout,⁵⁸ combined with knowledge of their functional roles and that inherited genetic variants influence their expression and are associated with gout, provides further evidence for epigenomic remodelling in the pathogenesis of gout. This would include epigenomic alteration of the innate immune system by soluble urate (training)⁷. Implication of the PIK3-AKT-mediated insulin signalling pathway, that may stimulate glycolysis and provide substrate for the Krebs cycle, suggests that the pathogenesis of gout involves insulin-stimulated production of substrate for epigenomic remodelling. Indeed, IGF1R and IRS1 are central to insulin signalling, are co-localized eQTLs, and have been implicated in the training mechanism⁹⁶. CHIP also associates with heart failure⁹⁷⁻⁹⁹ and deteriorating kidney function¹⁰⁰ and may link the etiologies of gout and co-morbid cardiorenal conditions via an inflammatory state. Supporting a role for the NLRP3-inflammasome, *TET2*-CHIP has been implicated in heart failure through the NLRP3-inflammasome and IL-1 β ¹⁰¹. *Tet2*-deficient mice have increased IL-1 β response to MSU crystals, with *Tet2*-deficient isolated macrophages having increased IL-1 β response to MSU crystal/lipopolysaccharide stimulation⁵⁸.

Testing lead genetic variants for association with increased IL-1 β production by PBMC *ex vivo* after stimulation with MSU crystals directly implicated *IL1RN* and *IL38*, emphasizing the IL-1 β pathway as crucial in gout. The genetic signal co-localizes with genetic control of expression of *IL1RN* (encoding IL-1RA, an IL-1 receptor antagonist) and *IL38*, suggesting that the genetic influence on risk of gout is mediated by the control of expression of either or

both genes. The G-allele associates with reduced expression of *IL1RN* in *ex vivo* PBMC upon stimulation with MSU crystal and C16.0 and lower levels of circulating IL1RA¹⁰². Consistent with these data, IL1RA acts as an inhibitor of IL-1 β action by competitive binding to the IL1R1 receptor.¹⁰³ This generates the hypothesis that IL1RA insufficiently compensates for IL-1 β induction and activity in gout¹⁰³. We did not detect genome-wide evidence for association at any genes encoding well-characterized components of the NLRP3 inflammasome or accessory molecules, nor innate molecules such as toll-like receptors, with the *IL1RN* and *IL1R1* loci representing the most well-characterized molecules that can be directly connected to IL-1 β . Rather, the new genes and pathways discovered in this study (e.g. epigenomic mechanisms) likely revolve around priming and regulation of the NLRP3 inflammasome response to monosodium urate crystals. In addition to CHIP-related genes, *FADS2* and *AQP10* discussed above, other genes highly ranked in the prioritization include *TMEM176B* (encoding a transmembrane calcium channel that inhibits NLRP3-inflammasome activation)¹⁰⁴, *SCAP* (encoding SREBP cleavage-activating protein, the SCAP-SREBP2 complex activates the inflammasome)¹⁰⁵, and *INSIG2* (encoding a binding partner of SCAP)¹⁰⁶.

A major limitation of our study is the dominance of participants of European ancestry (84.1%), with 9.2% of Latinx ancestry and only 3.6% and 3.1% for East Asian and African ancestry, respectively. This means that the new insights into the pathogenesis of gout presented here, and new interventions based on these insights, are not necessarily transferrable even to the included Latinx, East Asian and African ancestry populations, or to other non-European populations¹⁰⁷⁻¹⁰⁹, for example Indigenous populations in the Asia-Pacific region which suffer a high prevalence of and severe impact from gout^{1,110}. There is a

crisis of inequitable participation in genomics studies^{107,108}. Factors causing this situation include decades of inertia from Euro-centric researchers, funders and institutions, and deep-rooted mistrust of western institutions and researchers by minority and Indigenous populations as a result of colonization, misuse of samples and deficit framing. Increasing participation of non-European participants requires well-considered addressing of concerns, meaningful engagement with and maintenance of ongoing relationships with communities for the lifetime of the research, from initial collaboration and consultation, through recruitment and the research process to when findings are generated and new knowledge is returned to communities. It is most critical to build capability of genomics researchers from under-represented populations, and to establish data governance and protection that balances the interest of communities over that of researchers¹¹¹. The extant inequity contributes not only to under-powered GWAS but also to the lack of adequate publicly available essential genetic/genomic resources required for translation of genetic signals of association into mechanistic knowledge that include large genome sequence reference panels, body-wide eQTL datasets, and epigenomic datasets. Concerted international efforts are required to pool extant non-European genetics and genomics datasets to conduct GWAS and follow-up analyses equivalent to those done for Europeans.

Other limitations represent inherent current limitations of the field. For example, we performed co-localization analysis for eQTLs using tissues largely from GTEx and meQTL datasets generated from whole blood and kidney. With respect to meQTL in particular, additional datasets are needed across the gout disease state, for example the gut (important in urate excretion), the liver (urate production), the synovial lining (urate transport into the synovium), the kidney in different developmental stages, white blood cells and their subsets

during the gout flare (e.g. monocytes) and, *ex vivo*, monocyte response to urate crystals. While we did not include replication in our study design, high correlation between gout and urate effect sizes reduces our concern about false positives. Finally, some methods of gout diagnosis (self-report and use of administrative medication data) are not as direct as clinical diagnosis. However, we have previously reported that these survey definitions of gout contributing to the Global Genetics of Gout Consortium (one of the contributing datasets (**Table S1**)) have 82% sensitivity and 72% specificity¹¹², similar to a definition from the Study for Updated Gout Classification Criteria (SUGAR) that used five weighted items that included a clinical measure (hyperuricemia)¹¹².

To summarize, our study reveals a broad array of strong candidate genes and molecular processes in the pathogenesis of gout suitable for follow-up studies, for example implicating the prostate as contributing to hyperuricemia in men. In particular, we have provided new insights into the molecular mechanism of the acute inflammation in gout. Our findings, including implicating the CHIP phenomenon and other epigenetic regulators, further support epigenetic reprogramming (training) as a causal mechanism in gout.

Methods

Study participants and phenotype definition

Study participants were sourced from 13 cohorts^{11,113-121} (**Supplementary Note, Table S1**). Gout was defined according to self-reported diagnosis and/or use of urate-lowering medication, clinical diagnosis, and/or the American College of Rheumatology (ACR) gout classification criteria^{122,123} dependent on the information available in each source cohort. Participants from these cohorts were divided into four ancestral groups (African: AFR, East Asian: EAS, European: EUR, and Latinx: LAT) based on their self-reported ethnicity or genetic ancestry. This resulted in two African, five East Asian, ten European, and two Latinx case-control study sets for analysis. Written informed consent was acquired from all participants and each study had ethical approval from the appropriate local ethics committee. One key cohort was the UK Biobank¹²⁴ that was also used for genetic risk prediction, genetic correlation analysis with other phenotypes, Mendelian randomization and fine-mapping. 23andMe cohort participants¹²⁵ provided informed consent and participated in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical & Independent Review Services (E&I Review). Participants were included in the analysis on the basis of consent status as checked at the time data analyses were initiated. Ethical & Independent Review Services was recently acquired, and its new name as of July 2022 is Salus IRB (<https://www.versiticlinicaltrials.org/salusirb>).

Genotyping and imputation

Genotyping was performed separately for each of the 13 source cohorts. Cohort-specific genotyping and imputation platforms and post-imputation quality control filters are detailed in **Table S1**. Genotypes were imputed to one of the following reference panels: UK10K¹²⁶ +

1000 Genomes Project Phase 3 (all ancestries)¹²⁷, Haplotype Reference Consortium panel v1.1¹²⁸, 1000 Genomes Phase 3 (all ancestries), combined Haplotype Reference Consortium panel v1.1 and UK10K + 1000 Genomes Project Phase 3 (all ancestries), HapMap phase 2¹²⁹ (build 36), or population-specific Sequencing Initiative Suomi project v3 (build 38)¹³⁰. The genome coordinates of the build 36 and build 38 imputed genotypes were converted to their equivalent build 37 (hg19) coordinates using snptracker v1.0 (released Dec 2014)¹³¹ or GATK Lifter¹³², respectively. Post-imputation quality control filters per cohort included filters for Hardy-Weinberg equilibrium, genotype missingness, minor allele frequency, and imputation quality.

Study-specific association analysis

A genome-wide logistic regression analysis was conducted for each of the 19 case-control study sets separately with gout as a binary outcome. The regression model was adjusted for sex, age, genetic principal component vectors, and any necessary cohort-specific variables (e.g., genotyping platform) (**Table S1**). Regression analyses were repeated in male-only and female-only sub-sets for each case-control study set where possible, including the same adjusting variables except sex. Quality control steps applied to the per-study regression summary statistics included the removal of multi-allelic variants within and between study sets, exclusion of results for SNPs present in less than 5% of participants, and removal of any results outside the statistical bounds of each output (e.g. standard error = infinity). Variants with a minor allele frequency less than 0.1% or an absolute effect size (logOR) greater than 10 were also removed from the study-specific summary statistics.

Ancestry-specific and trans-ancestry meta-analysis

An inverse-variance weighted meta-analysis of the regression results for the full, male-only, and female-only subsets was conducted for each of the four ancestral groups using METAL¹³³. LD score regression analysis revealed no evidence of inflation due to factors such as population structure, therefore no genomic control correction was applied during this meta-analysis. SNPs with a heterogeneity I^2 statistic >95% were excluded from any further analysis. Variants analysed in <50% of the case-control study sets contributing to the meta-analysis (where there were more than two contributing cohorts) and/or variants that were analysed in <20% of all contributing samples were also excluded from any further analysis.

The ancestry-specific meta-analysis results were then used as an input for trans-ancestry meta-analysis with MANTRA^{v1}¹³⁴. Only SNPs with an effect size present in all four ancestry groups were included in the trans-ancestry meta-analysis. Genetic variants with a meta-analysis $P < 5 \times 10^{-8}$ or \log_{10} Bayes' factor ≥ 6.0 were considered statistically significant in the ancestry-specific and trans-ancestry meta-analyses, respectively (**Supplementary Notes**). Within the trans-ancestry meta-analysis, MANTRA was also used to calculate the posterior probability of heterogeneity which estimates the homogeneity in allelic effects across ancestral groups. A posterior probability > 0.90 indicates strong evidence for heterogeneity. In addition, loci with heterogenous effect sizes between sexes were identified by performing an inverse-variance weighted meta-analysis of the male-only and female-only ancestry-specific GWAS or trans-ancestry meta-analysis effect estimates. A SNP was considered significantly heterogeneous between sexes if the heterogeneity Q-statistic had a $P < 1 \times 10^{-6}$.

Identification of genome-wide significant signals and loci

All nominally significant SNPs were identified ($P < 1 \times 10^{-7}$ for ancestry-specific GWAS or \log_{10} Bayes factor > 5.0 for the trans-ancestry meta-analysis) and a ± 50 kb window of padding was added to the SNP chromosome position. The genomic overlap of these padded chromosome positions was then identified and the outer boundaries of these regions were created using GenomicRanges¹³⁵ v3.12. After defining these loci boundaries, any regions with ≤ 1 SNP classified as genome-wide significant ($P < 5 \times 10^{-8}$ or \log_{10} Bayes factor > 6.0 ¹³⁶) were disregarded in further loci definitions or analyses due to potential unreliability of single variant associations. Lead SNP(s) within each of the significant loci defined above were identified by conducting LD-based clumping using PLINKv1.9b4¹³⁷ with an ancestry-matched 1000 Genomes Project reference panel (**Supplementary Notes**). Significant loci were designated based on their chromosome and start/end position (in Mb) of the significant region (e.g. chr 5:129.52MB-131.88MB).

A regional association plot (Locus Zoom) was created for each locus (**Figure S2**) using an R script “LocusZoom-like Plots”¹³⁸ with GENCODE human genome build 37 (release 38) gene annotation file to define gene start/end positions and gene names (HGNC gene symbol)¹³⁹. Gene track information was coloured based on MAGMA²⁸ gene-based association analysis P -values (Supplementary Notes). After creating these regional association plots, each locus with multiple lead SNPs was visually inspected to determine whether the labelled SNPs represented a single association signal or multiple independent association signals. For the *SLC2A9* and *ABCG2* loci with an extremely strong association signal, only a single lead SNP was included to represent the locus even if multiple lead SNPs were identified by LD-based clumping (**Supplementary Notes**). Details of all excluded lead SNPs can be found in

Supplementary Notes. To identify additional associations, the European GWAS loci were analyzed with GCTA-COJO¹⁴⁰ using the UK Biobank cohort as a reference panel (**Supplementary Notes**). Due to a lack of adequately sized reference panels for the other ancestries, we did not conduct conditional analysis on the remaining GWAS datasets.

Previously unreported genome-wide significant loci and signals

To identify newly detected loci and signals we searched the literature for all previously reported SNPs associated with serum urate or gout. A search of GWAS Catalog¹⁴¹ was performed on 19th July 2022, using the keywords “urate”, “uric acid”, “hyperuric[a]emia”, and “gout.” This identified 68 studies published over the period of November 2007 to November 2021. All significant SNPs identified in these 68 studies were downloaded. Using build 38 genomic locations (our locus boundaries were converted to build 38 genomic locations using LiftOver¹³²), we identified any previous GWAS signal that fell within our significant loci boundaries defined above. LD between the lead SNP and all previously identified SNPs in the locus was calculated using 1000 Genomes reference panels in LDlinkR¹⁴² with ancestry-matching to the lead SNP. LD values were categorized into high ($r^2 \geq 0.8$), moderate ($0.8 > r^2 \geq 0.5$), low ($0.5 > r^2 \geq 0.1$), or no LD ($r^2 < 0.1$) groups to assess how similar the previously reported association signal was to the lead SNP. A locus was only considered new if none of the 68 urate and gout GWAS had previously reported a significant SNP within the locus boundaries.

Testing of gout-associated loci for association with urate

332,370 unrelated participants of European ancestry were selected from the UK Biobank using self-reported and genetic (PC-determined) ancestry information (**Supplementary**

Notes). Participants with evidence of gout (n = 7,131) based on hospital-diagnosed gout, self-reported gout, and use of urate-lowering medication, and those with no serum urate measurement (n = 15,531) were excluded, resulting in 309,708 participants in the association analysis for serum urate level. Variants with INFO < 0.3, MAF < 0.0001 and HWE $P < 1.0 \times 10^{-6}$ were removed. Association analysis was carried out using PLINK v1.9b6.10 with hard-called imputed genotype data, adjusted by age, sex, and PC1-40.

Genetically predicted risk of gout

A polygenic risk score was calculated from 289 lead variants from the European GWAS that were available in the UK Biobank. The SNPs were weighted by their effect size. The resulting PRS score was divided into 10 bins. Generalized linear modeling was used to regress the PRS score against gout, adjusted by age and sex, in 332,346 European participants from the UK Biobank. The lowest PRS score bins were excluded due to an absence of gout cases. This was repeated with 316 lead variants from the trans-ancestry meta-analysis in the same cohort. Sex-specific analysis was also undertaken for each of the PRS scores. For the female analysis, the top PRS bins were also excluded. Area under the receiver operating characteristic curve (AUROC) estimates were obtained using pROC¹⁴³.

LD score regression with UK Biobank traits and diseases

LD score regression²⁹ was used to run genetic correlation analysis of UK Biobank phenotypes with European gout GWAS summary statistics. Summary statistics for 934 primary phenotypes (**Supplementary Notes**) and baseline v1.1 reference LD scores for European ancestry was used. Since we included the FinnGen cohort in our European GWAS meta-analysis, we excluded all FinnGen phenotypes to avoid complete sample overlap

(Supplementary Notes). We considered any genetic correlation with our European gout GWAS to be significant if the p-value was less than a Bonferroni-corrected significance threshold of $P < 5.4 \times 10^{-5}$ (0.05/934). The resulting significantly correlated GWAS were then tested for horizontal pleiotropy using two-sample Mendelian randomization package TwoSampleMR¹⁴⁴.

Covariate-adjusted LD score regression

LD score intercepts, cell-type group (CTG), and cell-type specific (CTS) enrichment analysis for each ancestry (African, East Asian, European, and Latinx) were determined using covariate-adjusted LD score regression (cov-ldsc)²⁹. Baseline LD scores for each ancestry were generated using ancestry-specific PCs from the 1000 Genomes Project (Supplementary Notes), annotations from baseline v1.1, and LD window set to 20cM. Baseline LD scores for CTG and CTS analyses were generated similarly using the CTG and CTS annotations. The significance threshold for the coefficient p-value for the CTG analysis was set at 0.005 for a standard cut-off (for 10 cell-type groups) and 0.00125 for a conservative cut-off (for 10 cell-type groups and four ancestries), and the threshold for CTS analysis was set at 2.3×10^{-4} for a standard cut-off (for 220 cell-types) and 5.7×10^{-5} for a conservative cut-off (for 220 cell-types and four ancestries).

Statistical fine-mapping and credible set construction

European loci were fine-mapped using PAINTOR¹⁴⁵, FINEMAP⁴⁶, and the Bayes' factor (BF) approach^{134,146}. The region to be fine-mapped was set to the locus boundary described in **Table S2** unless the region was larger than 1 Mb; in such cases the fine-mapping region was defined as the 1 Mb region around the lead SNP, but in such a way that the region to be fine-

mapped did not exceed the locus boundary if the lead SNP was within 500 kb of the boundary (**Supplementary Notes**). For PAINTOR and FINEMAP, LD information from the UK Biobank was used (**Supplementary Notes**). All variants were aligned to the same allele as the UK Biobank and any variant with MAF that differed by > 5% were excluded from the fine-mapping analysis. Prior standard deviation for FINEMAP was set to 0.058 (**Supplementary Notes**) and shotgun stochastic search algorithm was used (--sss option) with the maximum number of causal variants in a locus set to five (default). Five annotations were used for PAINTOR: four annotations were chosen based on the relevance of the annotation with the European gout GWAS summary statistics (**Supplementary Notes**) and one annotation was included to give more weight to missense variants. PAINTOR was run with full enumeration (--enum option) assuming single causal variants except for those loci with evidence for multiple signals, in which case a maximum of three causal variants was assumed. For the BF approach, Bayes' factors of all variants were summed within the fine-mapping region and the posterior probability of each variant being causal in the region was calculated by dividing the variant's Bayes' factor with the total Bayes factor of the region. The 99% credible set was determined by including the variant with the highest posterior probability in the region until the cumulative posterior probability of the set was greater than 0.99.

Identification of compromised loci with SLALOM

To mitigate fine-mapping miscalibration when different genotyping arrays and imputation panels are used in meta-analysis, the summary statistics used for fine-mapping were checked with SLALOM⁴⁸. Conversion-unstable positions (CUPs)¹⁴⁷ were downloaded and reference LD from gnomAD (build 37) was calculated in the Non-Finnish European population for the

European loci and a mixture of African/African American, Latinx/Admixed American, East Asian, and European populations (proportional to the number of samples used in the trans-ancestry meta-analysis) were used for the trans-ancestry loci. A locus was identified as possibly miscalibrated if the locus contained at least one variant with $r^2 > 0.6$ with the lead variant (in the relevant reference population) and DENTIST-S¹⁴⁸ P -value was $<1 \times 10^{-4}$ in either the European or the trans-ancestry SLALOM analyses.

Candidate missense and non-coding variants

A pool of 1466 candidate variants was gathered from lead variants, conditionally associated variants and variants identified from fine-mapping. LD of 1425 non-coding variants was calculated using 1000 Genomes Project data (**Supplementary Notes**), and direct lead or high LD ($r^2 \geq 0.8$) missense and nonsense variants were identified using information from dbSNP (build 155). FATHMM scores for the 1425 variants were queried and the variants were overlaid for activity-by-contact enhancers (**Methods**).

Co-localization of signals of genetic association with eQTL

Lead SNPs from the European and trans-ancestry analyses, or a proxy if the lead variant was not present in GTEx, were used to query GTEx data for identification of *cis*-eQTL. For all the SNPs with a significant eQTL, a 1Mb region around the lead variant was used for co-localization analysis using the ‘coloc’ R package^{64,149}. A posterior probability of >0.5 for H4 (hypothesis 4) was taken as evidence for co-localization, which indicates the scenario that the association between gout and gene expression was due to the same functional variant. We also carried out *trans*-eQTL analysis combining GTEx and publicly available HiC data integrated using the CoDeS3D algorithm¹⁵⁰ and COLOC¹⁵¹ (**Supplementary Notes**).

Co-localization of signals of genetic association with methylation QTL (meQTL)

The GoDMC data set³⁹ was used to first identify all significant DNA methylation QTL (meQTL) within $\pm 1\text{Mb}$ window of the 444 lead European GWAS variants. For each pair of variant-CpG sites, a $\pm 500\text{kb}$ region around the lead GWAS variant was defined and tested for co-localization with the meQTL signal using the ‘coloc’ R package. Regions with < 100 variants with meQTL summary statistics for the CpG sites were excluded and regions with $\text{PPH4} \geq 0.8$ were considered as significant.

Enrichment analysis of transcription factor (TF) binding at meQTL CpG sites

1,544 TF ChIP-seq experiment data sets (344 TFs and 221 cell lines)⁴⁰ were downloaded (**Data Availability**). Eight TF ChIP-seq experiment datasets were excluded to ensure all of the ChIP-seq experiments were from human cell lines (**Supplementary Notes**), leaving 338 unique TFs for enrichment analysis. Positions for 232,477 independent CpG sites used in GoDMC were extracted. For each TF, the total number of CpG sites the TF overlapped ($\pm 50\text{bp}$) within the CpG sites was determined and 520 co-localized meQTL CpG sites identified. 338 two-by-two contingency tables were constructed and Fisher’s exact test was used to determine if there was significant enrichment of TF binding to the meQTL CpG sites.

Overlap of variants and CpG sites with activity-by-contact (ABC) enhancer region

ABC enhancer-gene connection data for 131 cell types and tissues with ABC-scores ≥ 0.015 ³⁵ was downloaded (**Data Availability**). The positions of candidate non-coding SNPs, lead SNPs that have co-localized eQTL, and CpG sites that have co-localized meQTL were

queried in the ABC data to determine whether the SNP and/or the CpG site was within an ABC enhancer region.

Gene prioritization for gout inflammation

To select the input list of candidate genes, association signal boundaries from all of the loci lists were used to select genes from GENCODE, and co-localized *cis*-/*trans*-eQTL genes not already in the list were added. Satisfying each of the following seven criteria scored the gene one point in the primary prioritization scheme: 1) having an eQTL co-localized with GWAS signal in whole blood; 2) having an eQTL in monocytes (ImmuNexUT⁶² or OneK1K¹⁵² datasets); 3) within a locus with a co-localized meQTL; 4) within a locus with gout association signal that also genetically associates with one or more of 36 white blood cell traits⁷⁸ (**Table S36** and **Supplementary Notes**); 5) differentially expressed in gout (**Supplementary Notes**); 6) expressed in GTEx whole blood tissue (**Supplementary Notes**); and 7) differentially expressed in monocytes stimulated with MSU crystals and/or lipopolysaccharide (LPS) (LPS vs MSU crystal, LPS vs phosphate-buffered saline control, MSU crystal vs PBS control)⁴³. Given that some of the categories used results that were derived using European ancestry and/or trans-ancestry data and could not be applied to all ancestral groups, the prioritisation scores were standardized based on the number of categories to which the gene was applied (depending from which ancestral group the gene was implicated) (**Supplementary Notes**). Following this, within each standardized score category, genes were secondarily ranked according to: 1) one of 47 genes containing a strong candidate missense causal variant (**Table 1**); 2) one of the 385 target genes of the activity-by-contact enhancer; 3) gene with FANTOM5 transcription start site (TSS) closest to the lead SNP. Given that not all genes had TSS information from the FANTOM5¹⁵³ dataset, scores for

those genes without TSS information were standardized (Supplementary Notes). Since multiple different SNPs can represent a specific locus (due to different lead SNP across ancestry and/or sex) the highest scoring SNP-gene row was selected to represent the gene.

Mendelian randomization analysis of CHIP vs gout

GWAS summary statistics for overall CHIP, *DNMT3A* CHIP and *TET2* CHIP were downloaded and filtered to only include variants with $P < 1 \times 10^{-6}$, variants in the European meta-analysis for gout, and variants with MAF > 1% in Europeans. For each GWAS, variants were then extracted from the UK Biobank before LD pruning to keep only variants at $r^2 < 0.2$ using 50 kb windows, testing every 5th variant (default parameters using PLINK 1.9b6.10). Summary statistics for these variants were extracted for all three CHIP classes along with gout. These summary statistics were used in a two-sample Mendelian randomization analysis, performed using the MendelianRandomization package in R 4.2.1. Beta and standard error values were transformed into log odds ratios and standard errors for each CHIP GWAS. For each CHIP trait, MR was run using three different models: weighted median, inverse variance-weighted and MR-Egger regression.

Drug repurposing analysis

We applied GREP⁶³ to perform the drug repositioning analysis using 476 significant genes in the MAGMA analysis ($P < 0.05 / (17,225 \text{ genes}) = 2.9 \times 10^{-6}$). GREP uses Fisher's exact tests to examine whether the 476 genes were enriched in genes targeted by drugs in a clinical indication category: Anatomical Therapeutic Chemical Classification System (ATC) or International Classification of Diseases 10 (ICD10) diagnostic code. ATC has 14 anatomical categories, which are further categorized into 85 detailed classes. GREP lists potentially

repositionable drugs targeting the gene set. The threshold for significant enrichment was set as $P = 0.05/10$, $0.05/85$, and $0.05/221$ in the ATC large set, the ATC detailed set, and the ICD10 set, respectively, adjusted by the Bonferroni correction for the number of categories. The ATC large set has 14 anatomical categories (e.g. M: MUSCULO-SKELETAL SYSTEM), which are further categorized into ~90 detailed classes (e.g. M04: ANTIGOUT PREPARATIONS) in the ATC detailed set.

Experimental studies

Analysis of single cell RNAseq prostate data

FASTQ files from two single cell RNAseq analyses in prostate tissue involving 3¹⁵⁴ and 6¹⁵⁵ samples (3 x 2 zones) were downloaded and analyzed using Cell Ranger v6.1.0 and Seurat v4.1.1 in R 4.0.2. For each pair of FASTQ files (containing forward and reverse reads respectively), the Cell Ranger count was used to produce a read count matrix for each sample. The Cell Ranger count output was read into R using Seurat, then a quality control procedure applied to ensure that cells had less than 20% mitochondrial reads and had greater than 80% complexity (\log_{10} gene count / UMI). Genes with fewer than 10 reads across all cells of each sample were not analyzed. Following quality control, read counts were scaled and transformed using the SCTransform function from Seurat. Samples were then integrated for each study using Seurat, with Henry et al. data¹⁵⁵ analyzed separately for the peripheral and transition/central zones. Uniform manifold approximation and projection (UMAP) for dimensionality reduction were performed for each sample, then cells were clustered prior to cluster identification. Expression of genes of interest within each cluster was done using the VlnPlot function from Seurat for each study.

Measurement of xanthine oxidoreductase (XOR) activity and urate levels in mice

C57Bl/6J mice were housed in the West Virginia University facility in specific pathogen free conditions. All experiments used only 7-week old male mice and were approved by the WVU Institutional Animal Care and Use Committee. Urate concentration was measured in surgically-dissected liver, prostate and seminal vesicle using HPLC coupled to electrochemical detection (ESA Coul-Array System) and expressed per mg protein as previously described⁶⁶. XOR¹¹²¹ 3212321 activity (1 Unit = 1 μ mol urate/min) was also assessed using reverse-phase HPLC coupled to electrochemical detection similar to above for urate but with preincubation with xanthine with and without allopurinol to determine contributions directly associated to XOR activity versus existing urate levels⁶⁶.

Data availability

The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Datasets will be made available at no cost for academic use (<https://research.23andme.com/collaborate/#dataset-access/>); 1000 Genomes Project Phase 3 data was downloaded from <http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/>; information on UK Biobank cohort can be viewed at <https://www.ukbiobank.ac.uk/>; GWAS Catalog (<https://www.ebi.ac.uk/gwas/>); GTEx data were downloaded from <https://gtexportal.org/home/datasets>; variant information from dbSNP was downloaded from https://ftp.ncbi.nih.gov/snp/latest_release/VCF/GCF_000001405.25.gz; CUPs used for SLALOM were downloaded from <https://github.com/cathaloruaidh/genomeBuildConversion>; GoDMC methylation QTL data were downloaded from <http://mqtl.db.godmc.org.uk/downloads>; RELI transcription factor ChIP-seq data https://tf.cchmc.org/external/RELI/RELI_public_data.tar.bz2; baseline LD score v1.1, cell-type specific, and cell-type group annotations were downloaded from <https://alkesgroup.broadinstitute.org/LDSCORE/>; functional annotations for PAINTOR were downloaded from <https://ucla.box.com/s/x47apvgv51au1rlmuat8m4zdhcniv2d>; LD score regression summary statistics of UK Biobank traits were downloaded from https://nealelab.github.io/UKBB_ldsc/downloads.html; ABC enhancer-gene connection data were downloaded from <ftp://ftp.broadinstitute.org/outgoing/lincRNA/ABC/AllPredictions.AvgHiC.ABC0.015.minus.150.ForABCPaperV3.txt.gz>; FATHMM scores for non-coding variants were obtained from <http://fathmm.biocompute.org.uk/>; ImmuNexUT eQTL data were downloaded from

<https://humandbs.biosciencedbc.jp/en/hum0214-v6>; OneK1K eQTL data were downloaded from https://onek1k.s3.ap-southeast-2.amazonaws.com/onek1k_eqtl_dataset.zip; Henry *et al.*¹⁵⁵ prostate single cell RNA-seq FASTQ data were downloaded from <https://www.gudmap.org/chaise/record/#2/RNASeq:Study/RID=W-RAHW>; Crowley *et al.*¹⁵⁴ prostate single cell RNA-seq count matrices were downloaded from GEO (GSE150692); CHIP summary statistics were downloaded from https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90102001-GCST90103000/; Susztak Kidney Biobank (<https://susztaklab.com/>); a list of differentially expressed genes in stimulated monocytes can be obtained from Table S2 in the original paper⁴³; GWAS data for white blood cell traits used in gene prioritization analysis (**Table S30**) (<https://www.ebi.ac.uk/gwas/>); FANTOM5 TSS data were downloaded from https://fantom.gsc.riken.jp/5/datafiles/phase1.3/extra/TSS_classifier/; HaploReg is available at <https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>; GeneHancer tracks were accessed through USCS; pathway analysis websites were <https://david.ncifcrf.gov/> and <https://maayanlab.cloud/Enrichr/>.

Coding tools availability

Code for “Locus Zoom-like plots” is available at <https://github.com/Geeketics/LocusZooms>;

PLINKv1.9 is available at <https://www.cog-genomics.org/plink/>;

GATK is available at <https://gatk.broadinstitute.org/hc/en-us>;

FINEMAP is available at <http://www.christianbenner.com/>;

PAINTOR is available at https://github.com/gkichaev/PAINTOR_V3.0;

LD score regression is available at <https://github.com/bulik/ldsc>;

cov-LD score regression is available at <https://github.com/immunogenomics/cov-ldsc>;

SLALOM is available at <https://github.com/mkanai/slalom>;

CoDeS3D is available at <https://github.com/alcamerone/codes3d>;

GCTA-COJO is available at <https://yanglab.westlake.edu.cn/software/gcta/>;

GREP is available at <https://github.com/saorisakaue/GREP>.

Tables and Figures

Figure 1: Numbers of significant loci and independent signals, across the ancestry-specific and trans-ancestry analyses and in the full (combined sexes), male-only, and female-only analyses. **A)** summarizes the cohorts used, the GWAS done, and loci detected. **B)** shows a Venn diagram of the overlap between significant loci across the full, male-only, and female-only GWAS amalgamated across all ancestries. **C)** shows an upset plot of the overlap between the significant independent signals in the single-ancestry and trans-ancestry analyses for the full cohort.

Figure 2: Association of polygenic risk score with gout in European participants of the UK Biobank in combined sexes, men, and women. **A)** shows the polygenic risk score bin distribution, **B)** shows the gout prevalence in different polygenic risk score bins, **C)** shows the risk of gout for each different risk score bin, compared to the most common bin (as visualized in panel A), and **D)** shows the area under the receiver operating characteristic curve graphs.

Figure 3: Genetic correlation between the European gout GWAS and UK Biobank GWAS traits. **A)** Volcano plot of genetic correlation between our European gout GWAS results and 934 UK Biobank GWAS traits. Points are coloured based on whether the equivalent correlation between our UK Biobank serum urate GWAS and the trait of interest was significant ($P < 5.35 \times 10^{-5}$). **B)** linear relationship between the genetic correlation results of our European gout GWAS and our UK Biobank serum urate GWAS. Points are coloured based on whether they were significant in both, one, or neither of the genetic correlation analyses. **C)** genetic correlation values (r_g) across 27 trait categories. In all plots, each point

represents the result of a genetic correlation analysis between our European gout GWAS and one of the 934 UK Biobank GWAS traits. Non-significant results are shown as transparent plot points for clarity.

Figure 4: Functional and pathway enrichment analyses of gout candidate genes. The DAVID database was used to identify GO Biological Function term, KEGG, and REACTOME pathways enriched in the gout GWAS dataset. Significance (FDR) of the enrichment is denoted on the y-axis, size of the circle denotes number of genes contributing to the enrichment term.

Figure 5: Genes prioritized for a role in gouty inflammation. **A)** 117 genes with a normalized prioritization score ≥ 4 are listed from highest to lowest score. The seven prioritization categories (left), three function agnostic categories (middle), and the normalized scores (right) are given for each gene. Cells are colored if the gene gained a point in the prioritization/function agnostic scores based on the criteria of that category and crossed if the category data was unavailable for that gene. Red gene labels represent those that were identified as a *trans*-eQTL. **B)** ideogram showing the genomic location of the 117 genes with a prioritization score ≥ 4 . Bolded gene labels represent those that had a function agnostic score ≥ 1 and red gene labels represent those that were identified as a *trans*-eQTL. Light blue highlighting within the ideogram chromosomes indicates the genomic location of all significant loci identified, amalgamated across all ancestry-, trans-ancestry, and sex-specific analyses.

Figure 6: *XDH* expression and xanthine oxidoreductase (XOR) activity in the prostate.

A) Locus Zoom plots of genetic association at the *XDH* locus with gout (European full analysis; left) and serum urate in Europeans (UK Biobank; right). Each genetic variant is represented by a single dot plotted according to genomic position on the x-axis with strength of evidence for association ($-\log_{10}P$) on the y-axis. The lead variant is highlighted with a purple diamond; other variants are colored according to their LD with the lead variant (strong (red) to weak (dark blue)). **B)** the European male gout (top left) GWAS signal co-localizes with *XDH* expression in prostate tissue (GTEx v8; bottom left), but not with the European female gout GWAS signal (top right). Shown also is the expression signal of *XDH* in the liver (GTEx v8; bottom right). **C)** XOR activity and urate levels in prostate, liver, and seminal vesicle tissue from seven-week old C57Bl/6 male mice. A Kruskal-Wallis test was used to determine whether the differences between tissues were significant. **D)** and **E)** bar plots show the percentage of cells expressing *XDH* in a given cell cluster, alongside three urate transporter genes expressed in the prostate (*ABCG2*, *SLC2A9*, *ABCC4*) in prostate cell clusters. Single cell RNA-seq data were obtained from Crowley et al.¹⁵⁴ (panel D) and Henry et al.¹⁵⁵ (panel E).

Figure 7: Mendelian randomization of CHIP vs gout for all CHIP, *DNMT3A* CHIP, and *TET2* CHIP.

A), **C)**, and **E)** are plots of the relative effect sizes of CHIP-associated variants on gout for each of the three CHIP types, respectively. Overlaid lines indicate the Mendelian randomization estimates from weighted median, inverse variance weighted, or MR-Egger regression. **B)**, **D)**, and **F)** show the Mendelian randomization estimates as forest plots for each of the three CHIP types, respectively, including the MR-Egger intercept for each model.

Figure 8: *DGAT2*: Example of genome organization at a candidate immune-priming lncRNA locus. ENCODE H3K4me3 signal track from CD14+ monocytes indicates enrichment at the promoters of *DGAT2*, the lncRNA *RP11-535A19.2*, and *UVRAG*. ENCODE CCCTC-binding factor (CTCF) signal track from neutrophils and CD14+ monocytes indicates CTCF binding at the SNP *rs11236533*. Genehancer connections are indicated in green and illustrate physical connections (Hi-C) between *rs11236533*, which disrupts a CTCF binding site and additional maximally associated SNPs at two Genehancer regulatory elements. Red and blue dots indicate the CpG locations that are associated with co-localized meQTL and the colour denotes direction of effect of the gout risk allele (red = higher methylation, blue = lower methylation).

Figure 9: Linking of urate metabolism and transport, insulin signalling, the Krebs cycle, and epigenomic reprogramming with candidate gout-associated genes. Candidate genes are encircled in bold lines, CHIP-implicated genes in red bold lines.

Table 1: Table of missense lead variants or variants that are in high LD with lead variants. Candidate causal variants were drawn from Table S19 as either a lead variant (including from conditional COJO analysis) or in very strong LD ($r^2 \geq 0.98$) with a lead variant (including from conditional COJO analysis). 1, indicates LD in European, unless otherwise stated; 2, indicates frequency of risk allele in European, unless otherwise stated.

Table 2: Table of candidate immune-priming lncRNAs. Candidate immune-priming lncRNAs were extracted from **Table 120** based on the lead variant having a cis-eQTL for both a lncRNA and a protein-coding gene, and the gene having a high prioritization score in **Table S30**. SNP positions are noted in human genome build GRCh38 coordinates. a,

prioritization score used *rs28407119* (European male-only lead variant) as the locus SNP. b, prioritization score used *rs4669524* (trans-ancestry full (combined sexes) lead variant) as the locus SNP. c, prioritization score used *rs112537099* (European male-only lead variant) as the locus SNP.

Ethics statement

For the 23andMe Inc. Cohort participants provided informed consent and participated in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical and Independent Review Services (www.eandireview.com). The UK Biobank (UKBB) was undertaken with ethical approval from the North West Multi-Centre Research Ethics Committee of the UK. GlobalGout obtained ethical approval from the following committees: the New Zealand Multiregional Ethics Committee (MEC05/10/130); the Northern Y Region Health Research Ethics Committee (Ngāti Porou Hauora Charitable Trust study; NTY07/07/074); Research and Ethics Committee, Repatriation General Hospital, South Australia (32/08); Research Ethics Committee, University of New South Wales; Ethikkommission, Technische Universität Dresden (EK 8012012); South East Scotland Research Ethics Committee (04/S1102/41); Commission Cantonale (VD) D'éthique de la Recherche sur l'être Humain, Université de Lausanne; Commissie Mensgebonden Onderzoek regio Arnhem—Nijmegen; Partners Health Care System Institutional Review Board. The Institutional Review Board of the Kaiser Foundation Research Institute provided ethical approval for the Kaiser Permanente sample set. The FinnGen study was approved by the Coordinating Ethical Committee of the Hospital District of Helsinki and Uusimaa. The ethics review board at the Affiliated Hospital of Qingdao University approved the study in China. In Japan ethical approvals were provided by the institutional ethical committees of the National Defense Medical College, Nagoya University and RIKEN. The Korean Association Resource (KARE) was approved by the institutional review board of the Korea National Institute of Health. The FAST study and Generation Scotland was ethically approved by the UK Multi-Centre Research Ethics Committee (Reference number: 2011-001883-23) and the

NHS Tayside Committee on Medical Research Ethics (REC Reference Number:
05/S1401/89).

Acknowledgements

We would like to thank the research participants and employees of 23andMe for making this work possible. The following members of the 23andMe Research Team contributed to this study: Stella Aslibekyan, Adam Auton, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, Katarzyna Bryc, Emily Bullis, Daniella Coker, Gabriel Cuellar Partida, Devika Dhamija, Sayantan Das, Sarah L. Elson, Nicholas Eriksson, Teresa Filshtein, Alison Fitch, Kipper Fletez-Brant, Pierre Fontanillas, Will Freyman, Julie M. Granka, Karl Heilbron, Alejandro Hernandez, Barry Hicks, David A. Hinds, Ethan M. Jewett, Yunxuan Jiang, Katelyn Kukar, Alan Kwong, Keng-Han Lin, Bianca A. Llamas, Maya Lowe, Jey C. McCreight, Matthew H. McIntyre, Steven J. Micheletti, Meghan E. Moreno, Priyanka Nandakumar, Dominique T. Nguyen, Elizabeth S. Noblin, Jared O'Connell, Aaron A. Petrakovitz, G. David Poznik, Alexandra Reynoso, Morgan Schumacher, Anjali J. Shastri, Janie F. Shelton, Jingchunzi Shi, Suyash Shringarpure, Qiaojuan Jane Su, Susana A. Tat, Christophe Toukam Tchakouté, Vinh Tran, Joyce Y. Tung, Xin Wang, Wei Wang, Catherine H. Weldon, Peter Wilton, Corinna D. Wong.

We thank the participants and staff of the UK Biobank study for their important contributions. This research has been conducted using the UK Biobank resource under application number 12611. We want to acknowledge the participants and investigators of the FinnGen study. This study was supported by grants from the New Zealand Health Research of New Zealand (08/075, 11/1075, 14/527), Arthritis New Zealand, Lottery Health New Zealand, JSPS KAKENHI Grant Numbers (20H00566, 21KK0173, 17H04128, 22H00476, 20K23152, 21H03350, 221S0002, 16H06279 [PAGS], 16H06277 [CoBiA], 20H00568), AMED (JP21gm4010006, JP22km0405211, JP22ek0410075, JP22km0405217,

JP22ek0109594), JST Moonshot R&D (JPMJMS2021, JPMJMS2024), Takeda Science Foundation, Bioinformatics Initiative of Osaka University Graduate School of Medicine, the Gout and Uric Acid Foundation of Japan and the Ministry of Defense of Japan, the National Natural Science Foundation of China (82220108015) and National Key Research and Development Program of China (2022YFE0107600; 2022YFC2503300). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK, the Wellcome Trust (Wellcome Trust Strategic Award “Stratifying Resilience and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z) and by MRC University Unit grant MC_UU_00007/10 (QTL in Health and Disease programme).

Declaration of Interests

W.W. and S.S. are employed by and hold stock or stock options in 23andMe, Inc.

& Japan Gout Genomics Consortium (Japan Gout)

Ituro Inoue⁷⁵, Toru Shimizu⁷⁶, Hiroshi Ooyama⁷⁷, Keiko Ooyama⁷⁷, Mitsuo Nagase⁷⁸, Yuji Hidaka⁷⁹, Kenji Wakai⁸⁰, Yohko Nakamura⁸¹, Hiroto Narimatsu⁸², Kiyonori Kuriki⁸³, Sadao Suzuki⁸⁴, Hidemi Ito⁸⁵, Asahi Hishida⁸⁰, Takashi Tamura⁸⁰, Yoshikuni Kita⁸⁶, Teruhide Koyama⁸⁷, Kokichi Arisawa⁸⁸, Hiroaki Ikezaki⁸⁹, Keitaro Tanaka⁹⁰, Chihaya Koriyama⁹¹, Yuzo Takada⁹², Takahiro Nakamura⁹³, Miki Ueno⁹⁴, Toshimitsu Ito⁹⁵, Satoko Iwasawa⁹⁶, Satoko Suzuki⁹⁶, Yuka Miyoshi⁹⁶, Hiroshi Nakashima⁹⁶, Yutaka Sakurai⁹⁶, and Masashi Tsunoda⁹⁶.

75. Human Genetics Laboratory, National Institute of Genetics, Shizuoka, Japan

76. Midorigaoka Hospital, Osaka, Japan

77. Ryougoku East Gate Clinic, Tokyo, Japan

78. Nagase Clinic, Tokyo, Japan

79. Akasaka Central Clinic, Tokyo, Japan

80. Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan

81. Cancer Prevention Center, Chiba Cancer Center Research Institute, Chiba, Japan

82. Cancer Prevention and Control Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan

83. Laboratory of Public Health, Division of Nutritional Sciences, School of Food and Nutritional Sciences, University of Shizuoka, Shizuoka, Japan

84. Department of Public Health, Nagoya City University Graduate School Medical Science, Aichi, Japan

85. Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Aichi, Japan

86. Faculty of Nursing Science, Tsuruga Nursing University, Fukui, Japan

87. Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

88. Department of Preventive Medicine, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima, Japan

89. Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan

90. Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan

91. Department of Epidemiology and Preventive Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

92. Faculty of Medical Science, Teikyo University of Science, Tokyo, Japan

93. Laboratory for Mathematics, National Defense Medical College, Saitama, Japan

94. Division of Nursing, National Defense Medical College, Saitama, Japan

95. Department of Internal Medicine, Self-Defense Forces Central Hospital, Tokyo, Japan

96. Department of Preventive Medicine and Public Health, National Defense Medical College, Saitama, Japan

References

1. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. *Nat Rev Rheumatol*. 2015;11:649-662.
2. Safiri S, Kolahi AA, Cross M, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. *Arthritis Rheumatol*. 2020;72:1916-1927.
3. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. *Am J Med*. 2012;125:679-687.
4. Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet*. 2016;388:2039-2052.
5. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature*. 2006;440:237-241.
6. Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. *Nat Med*. 2014;20:511-517.
7. Cabão G, Crișan TO, Klück V, et al. Urate - induced immune programming: Consequences for gouty arthritis and hyperuricemia. *Immunol Rev*. 2020;294:92-105.
8. Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. *Science*. 2016;352(6284).
9. Tin A, Marten J, Kuhns VLH, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. *Nature Genet*. 2019;41:1459-1474.
10. Kawamura Y, Nakaoka H, Nakayama A, et al. Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. *Ann Rheum Dis*. 2019;78(10):1430-1437.
11. Li C, Li Z, Liu S, et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. *Nat Commun*. 2015;6:7041.
12. Sulem P, Gudbjartsson DF, Walters GB, et al. Identification of low-frequency variants associated with gout and serum uric acid levels. *Nat Genet*. 2011;43:1127-1130.
13. Matsuo H, Yamamoto K, Nakaoka H, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. *Ann Rheum Dis*. 2016;75:652-659.
14. Nakayama A, Nakaoka H, Yamamoto K, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. *Ann Rheum Dis*. 2017;76:869-877.
15. Nakayama A, Nakatochi M, Kawamura Y, et al. Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. *Ann Rheum Dis*. 2020;79:657-665.
16. Zhou W, Kanai M, Wu K-HH, et al. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. *Cell Genomics*. 2022;2:100192.
17. Champion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. *Am J Med*. 1987;82(3):421-426.
18. Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. *Ann Rheum Dis*. 2018;77:1048-1052.
19. Dalbeth N, House ME, Aati O, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. *Ann Rheum Dis*. 2015;74:908-911.
20. Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. *Nat Rev Rheumatol*. 2018;14:341-353.
21. Toyoda Y, Nakatoshi M, Nakayama A, et al. SNP-based heritability estimates of gout and its subtypes determined by genome-wide association studies of clinically defined gout. *Rheumatology*. 2022; Online ahead of print.
22. Cadzow M, Merriman TR, Dalbeth N. Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank. *Arthritis Res Ther*. 2017;19:181.
23. Sandoval-Plata G, Morgan K, Abhishek A. Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank. *Ann Rheum Dis*. 2021;80:2020-2026.
24. Takei R, Sumpter NA, Phipps-Green A, et al. Correspondence on ‘Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to

- gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank'. *Annals of the Rheumatic Diseases*. 2021; Online ahead of print.
25. Kanai M, Akiyama M, Takahashi A, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nature Genet*. 2018;50:390-400.
 26. Klück V, van Deuren RC, Cavalli G, et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. *Ann Rheum Dis*. 2020;79:536-544.
 27. Sumpter NA, Takei R, Leask MP, et al. Genetic association studies of the progression from hyperuricemia to gout. *Rheumatology*. 2022;61:e139-e140.
 28. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comp Biol*. 2015;11:e1004219.
 29. Bulik-Sullivan BK, Loh P-R, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genet*. 2015;47:291-295.
 30. Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. *Arthritis Rheumatol*. 2019;71:991-999.
 31. Yang QO, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. *Circ-Cardiovasc Genet*. 2010;3:523-530.
 32. Yuan S, Wang L, Sun J, et al. Genetically predicted sex hormone levels and health outcomes: phenome-wide Mendelian randomization investigation. *Int J Epidemiol*. 2022; Online ahead of print.
 33. Luo Y, Li X, Wang X, et al. Estimating heritability and its enrichment in tissue-specific gene sets in admixed populations. *Hum Mol Genet*. 2021;30:1521-1534.
 34. Qiu C, Huang S, Park J, et al. Renal compartment-specific genetic variation analyses identify new pathways in chronic kidney disease. *Nature Med*. 2018;24:1721-1731.
 35. Nasser J, Bergman DT, Fulco CP, et al. Genome-wide enhancer maps link risk variants to disease genes. *Nature*. 2021;593:238-243.
 36. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. *Nature*. 2002;417:447-452.
 37. Badii M, Gaal O, Cleophas MC, et al. Urate-induced epigenetic modifications in myeloid cells. *Arthritis Res Ther*. 2021;23:202.
 38. Wang Z, Zhao Y, Phipps Green A, et al. Differential DNA methylation of networked signaling, transcriptional, innate and adaptive immunity, and osteoclastogenesis genes and pathways in gout. *Arthritis Rheumatol*. 2020;72:802-814.
 39. Min JL, Hemani G, Hannon E, et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nature Genet*. 2021;53:1311-1321.
 40. Harley JB, Chen X, Pujato M, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. *Nature Genet*. 2018;50:699-707.
 41. Hong J, Li S, Markova DZ, et al. Bromodomain - containing protein 4 inhibition alleviates matrix degradation by enhancing autophagy and suppressing NLRP3 inflammasome activity in NP cells. *J Cell Physiol*. 2020;235:5736-5749.
 42. Hao K, Jiang W, Zhou M, et al. Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis. *Intl J Biol Sci*. 2020;16:3163.
 43. Cobo I, Cheng A, Murillo-Saich J, et al. Monosodium urate crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response. *Cell Rep*. 2022;38:110489.
 44. Liu H, Doke T, Guo D, et al. Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease. *Nature Genet*. 2022;54:950-962.
 45. Xie Z, Bailey A, Kuleshov MV, et al. Gene set knowledge discovery with enrichr. *Curr Protocols*. 2021;1:e90.
 46. Benner C, Spencer CC, Havulinna AS, et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics*. 2016;32:1493-1501.
 47. Kichaev G, Yang W-Y, Lindstrom S, et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. *PLoS Genet*. 2014;10:e1004722.
 48. Kanai M, Elzur R, Zhou W, et al. Meta-analysis fine-mapping is often miscalibrated at single-variant resolution. *medRxiv*. 2022; doi: <https://doi.org/10.1101/2022.03.16.22272457>
 49. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet*. 2011;88:76-82.
 50. Zhao B, Tu C, Shen S, Qu J, Morris ME. Identification of potential megalin/cubilin substrates using extensive proteomics quantification from kidney megalin-knockdown mice. *AAPS J*. 2022;24:1-14.

51. Shihab HA, Gough J, Cooper DN, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum Mut.* 2013;34:57-65.
52. Dennis G, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol.* 2003;4:P3.
53. ter Horst R, Jaeger M, Smeekens SP, et al. Host and environmental factors influencing individual human cytokine responses. *Cell.* 2016;167:1111-1124.
54. Backman JD, Li AH, Marcketta A, et al. Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature.* 2021;599:628-634.
55. Srivastava A, Chopra S, Dasgupta P. Biochemical analysis of human seminal plasma ii. Protein, non-protein nitrogen, urea, uric acid and creatine. *Andrologia.* 1984;16:265-268.
56. Park JJ, Roudier MP, Soman D, et al. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. *BMJ Open.* 2014;4:e005308.
57. Kar SP, Quiros PM, Gu M, et al. Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. *Nat Genet.* 2022;54:1155-1166.
58. Agrawal A, Niroula A, Cunin P, et al. *TET2*-mutant clonal hematopoiesis and risk of gout. *Blood.* 2022;140:1094-1103.
59. Merriman TR, Joosten LA. CHIP and gout: trained immunity? *Blood.* 2022;140:1054-1056.
60. Fanucchi S, Fok ET, Dalla E, et al. Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments. *Nature Genet.* 2019;51:138-150.
61. Reddy MA, Amaram V, Das S, et al. lncRNA DRAIR is downregulated in diabetic monocytes and modulates the inflammatory phenotype via epigenetic mechanisms. *JCI Insight.* 2021;6:e143289.
62. Ota M, Nagafuchi Y, Hatano H, et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. *Cell.* 2021;184:3006-3021.
63. Sakaue S, Okada Y. GREP: genome for REPositioning drugs. *Bioinformatics.* 2019;35:3821-3823.
64. Boocock J, Leask M, Okada Y, et al. Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. *Hum Mol Genet.* 2020;29(6):923-943.
65. Nakatochi M, Kanai M, Nakayama A, et al. Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. *Comm Biol.* 2019;2:115.
66. Harmon DB, Mandler WK, Sipula IJ, et al. Hepatocyte-specific ablation or whole-body inhibition of xanthine oxidoreductase in mice corrects obesity-induced systemic hyperuricemia without improving metabolic abnormalities. *Diabetes.* 2019;68:1221-1229.
67. Zhang H, Lu J, Zhang R, et al. Determination of uric acid in seminal plasma and correlation between seminal uric acid and semen parameters. *Natl J Urol.* 2007;13:1016-1019.
68. Dalbeth N, House ME, Gamble GD, et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. *Ann Rheum Dis.* 2013;72:1868-1873.
69. Patel AV, Gaffo AL. Managing gout in women: current perspectives. *J Inflamm. Res.* 2022;15:1591.
70. Sumpter NA, Cadzow M, Reynolds RJ, et al. Analysis of common gout comorbidities in the UK Biobank cohort reveals sex-specific effects and genetic differentiation. *Arthritis & Rheumatism.* 2020;72:S10.
71. Mandal AK, Leask M, Sumpter NA, et al. Genetic and physiological effects of insulin-like growth factor-1 (IGF-1) on human urate homeostasis. *J Am Soc Nephrol.* 2022; In press.
72. Gazal S, Weissbrod O, Hormozdiari F, et al. Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity. *Nature Genetics.* 2022;54:827-836.
73. Mountjoy E, Schmidt EM, Carmona M, et al. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. *Nature Genet.* 2021;53:1527-1533.
74. Legrand-Poels S, Esser N, L'homme L, et al. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. *Biochem Pharmacol.* 2014;92:131-141.
75. Chu X, Jaeger M, Beumer J, et al. Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease. *Genome Biol.* 2021;22:198.
76. Sibbons CM, Irvine NA, Pérez-Mojica JE, et al. Polyunsaturated fatty acid biosynthesis involving $\Delta 8$ desaturation and differential DNA methylation of FADS2 regulates proliferation of human peripheral blood mononuclear cells. *Front Immunol.* 2018;9:432.
77. Saag KG, Khanna PP, Keenan RT, et al. A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. *Arthritis Rheumatol.* 2021;73:1533-1542.
78. Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. *Cell.* 2016;167:1415-1429.

79. Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. *Nature Genet.* 2021;53:1415-1424.
80. Terao C, Yoshifuji H, Matsumura T, et al. Genetic determinants and an epistasis of LILRA3 and HLA-B* 52 in Takayasu arteritis. *Proc Natl Acad Sci.* 2018;115:13045-13050.
81. Mylona EE, Mouktaroudi M, Crisan TO, et al. Enhanced interleukin-1 β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. *Arthritis Res Ther.* 2012;14(4):R158.
82. Temmoku J, Fujita Y, Matsuoka N, et al. Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib. *Modern Rheumatol.* 2021;31:270-275.
83. Calvo-Aranda E, Sanchez-Aranda FM. Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra. *Rheumatol.* 2021;60:e375-e377.
84. Mokuda S, Kanno M, Takasugi K, et al. Tocilizumab improved clinical symptoms of a patient with systemic tophaceous gout who had symmetric polyarthritis and fever: an alternative treatment by blockade of interleukin-6 signaling. *SAGE Open Med Case Rep.* 2014;2:2050313X13519774.
85. Pinto JL, Mora GE, Fernández-Avila DG, et al. Tocilizumab in a patient with tophaceous gout resistant to treatment. *Reumatología Clínica* 2013;9:178-180.
86. Gotfryd K, Mósca AF, Missel JW, et al. Human adipose glycerol flux is regulated by a pH gate in AQP10. *Nature Comm.* 2018;9:4749.
87. Compan V, Baroja-Mazo A, López-Castejón G, et al. Cell volume regulation modulates NLRP3 inflammasome activation. *Immunity.* 2012;37:487-500.
88. Chirayath TW, Pham N, Duranton C, et al. Inflammation induced by monosodium urate and calcium pyrophosphate crystals depends on osmolarity and aquaporin channels. *Ann Rheum Dis.* 2022;81:S1.
89. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. *Plos Genetics.* 2009;5:e1000504.
90. Zhao Y, Xu L, Tian D, et al. Effects of sodium - glucose co - transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta - analysis of randomized controlled trials. *Diabetes, Obesity Metab.* 2018;20:458-462.
91. Zhao SS, Rajasundaram S, Karhunen V, et al. Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study. *Sem Arthritis Rheum.* 2022;56:152058.
92. Pearson DL, Dawling S, Walsh WF, et al. Neonatal pulmonary hypertension: urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. *NEJM* 2001;344:1832-1838.
93. Kettunen J, Demirkan A, Würtz P, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nature Comm.* 2016;7:11122.
94. Riksen NP, Netea MG. Immunometabolic control of trained immunity. *Mol Aspects Med.* 2021;77:100897.
95. Tran KA, Dillingham CM, Sridharan R. The role of α -ketoglutarate-dependent proteins in pluripotency acquisition and maintenance. *J Biol Chem.* 2019;294:5408-5419.
96. Bekkering S, Arts RJ, Novakovic B, et al. Metabolic induction of trained immunity through the mevalonate pathway. *Cell.* 2018;172:135-146.
97. Yu B, Roberts MB, Raffield LM, et al. Association of clonal hematopoiesis with incident heart failure. *J Am Coll Cardiol.* 2021;78:42-52.
98. Kiefer KC, Cremer S, Pardali E, et al. Full spectrum of clonal haematopoiesis - driver mutations in chronic heart failure and their associations with mortality. *ESC Heart Fail.* 2021;8:1873-1884.
99. Pascual-Figal DA, Bayes-Genis A, Díez-Díez M, et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. *J Am Coll Cardiol.* 2021;77:1747-1759.
100. Vlasschaert C, McNaughton AJ, Chong M, et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. *J Am Soc Nephrol.* 2022;33:985-995.
101. Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1 β /NLRP3 inflammasome. *J Am Coll Cardiol.* 2018;71:875-886.
102. Gaal O, Crisan T, Joosten L. Gout-associated SNP at the IL1RN-IL1F10 region is functionally linked to altered cytokine production in PBMCs of patients with gout and controls *Gout Urate Cryst Dep Dis.* 2023;In press.
103. Klück V, Liu R, Joosten LA. The role of interleukin-1 family members in hyperuricemia and gout. *Joint Bone Spine.* 2021;88:105092.

104. Segovia M, Russo S, Jeldres M, et al. Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation. *Canc Cell*. 2019;35(5):767-781.
105. Guo C, Chi Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. *Immunity*. 2018;49:842-856.
106. Yan R, Cao P, Song W, et al. A structure of human Scap bound to Insig-2 suggests how their interaction is regulated by sterols. *Science*. 2021;371:eabb2224.
107. Martschenko DO, Smith M. Genes do not operate in a vacuum, and neither should our research. *Nature Genet*. 2021;53:255-256.
108. Potenski C. Necessary voices. *Nature Genetics*. 2020;52:135-135.
109. Gurdasani D, Barroso I, Zeggini E, Sandhu MS. Genomics of disease risk in globally diverse populations. *Nature Reviews Genetics*. 2019;20:520-535.
110. Wong PK, Ng BC, Mitchell J, et al. The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney. *Intern Med J*. 2022; Online ahead of print.
111. Tsosie KS, Fox K, Yracheta JM. Genomics data: the broken promise is to Indigenous people. *Nature*. 2021;591:529-530.
112. Dalbeth N, Schumacher HR, Fransen J, et al. Survey definitions of gout for epidemiologic studies: comparison with crystal identification as the gold standard. *Arthritis Care Res*. 2016;68:1894-1898.
113. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. *The Lancet*. 2020;396:1745-1757.
114. Kvale MN, Hesselson S, Hoffmann TJ, et al. Genotyping informatics and quality control for 100,000 subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. *Genetics*. 2015;200:1051-1060.
115. Chang S-J, Toyoda Y, Kawamura Y, et al. A meta-analysis of genome-wide association studies using Japanese and Taiwanese has revealed novel loci associated with gout susceptibility. *Human Cell*. 2022;35:767-770.
116. Kurki MI, Karjalainen J, Palta P, et al. FinnGen: Unique genetic insights from combining isolated population and national health register data. *medRxiv*. 2022; doi: <https://doi.org/10.1101/2022.03.03.22271360>
117. Köttgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet*. 2013;45:145-154.
118. Ottosson F, Smith E, Melander O, Fernandez C. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. *J Clin Endocrinol Metab*. 2018;103:3060-3069.
119. Lindström S, Loomis S, Turman C, et al. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. *PLoS One*. 2017;12:e0173997.
120. Boutin NT, Schechter SB, Perez EF, et al. The Evolution of a Large Biobank at Mass General Brigham. *Journal of Personalized Medicine*. 2022;12(8):1323.
121. Shin J, Kim Y, Kong M, Lee C. Genetic architecture for susceptibility to gout in the KARE cohort study. *J Hum Genet*. 2012;57:379-384.
122. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheumatol*. 2015;67:2557-2568.
123. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis Rheum*. 1977;20:895-900.
124. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203-209.
125. Eriksson N, Macpherson JM, Tung JY, et al. Web-based, participant-driven studies yield novel genetic associations for common traits. *PLoS Genet*. 2010;6:e1000993.
126. Walter K, Min JL, Huang J, et al. The UK10K project identifies rare variants in health and disease. *Nature*. 2015;526:82-90.
127. Autin A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. *Nature*. 2015;526:68-74.
128. McCarthy S, Das S, Kretzschmar M, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nature Genet*. 2016;48:1279-1283.

129. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007;449:851-861.
130. Lim ET, Würtz P, Havulinna AS, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet*. 2014;10:e1004494.
131. Deng J-E, Sham PC, Li M-X. SNPTracker: a swift tool for comprehensive tracking and unifying dbSNP rs IDs and genomic coordinates of massive sequence variants. *G3: Genes, Genomes, Genetics*. 2016;6:205-207.
132. Repository BIG. Picard Toolkit. <https://broadinstitute.github.io/picard/>. 2019.
133. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190-2191.
134. Morris AP. Transethnic meta - analysis of genomewide association studies. *Genet Epidemiol*. 2011;35:809-822.
135. Lawrence M, Huber W, Pages H, et al. Software for computing and annotating genomic ranges. *PLoS Comp Biol*. 2013;9:e1003118.
136. Wang X, Chua H-X, Chen P, et al. Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies. *Hum Mol Genet*. 2013;22:2303-2311.
137. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559-575.
138. Major TJ, Takei R. LocusZoom-like Plots for GWAS Results (v2.1). *Zenodo*. 2021;<https://doi.org/10.5281/zenodo.5154379>.
139. Frankish A, Diekhans M, Ferreira A-M, et al. GENCODE reference annotation for the human and mouse genomes. *Nucl Acids Res*. 2019;47:D766-D773.
140. Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nature Genet*. 2012;44:369-375.
141. Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucl Acids Res*. 2019;47:D1005-D1012.
142. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinform*. 2015;31:3555-3557.
143. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinform*. 2011;12:77.
144. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *eLife*. 2018;7:e34408.
145. Kichaev G, Bhatia G, Loh P-R, et al. Leveraging polygenic functional enrichment to improve GWAS power. *Am J Hum Genet*. 2019;104:65-75.
146. Mahajan A, Go MJ, Zhang W, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nature Genet*. 2014;46:234-244.
147. Ormond C, Ryan NM, Corvin A, Heron EA. Converting single nucleotide variants between genome builds: from cautionary tale to solution. *Brief Bioinform*. 2021;22(5):bbab069.
148. Chen W, Wu Y, Zheng Z, et al. Improved analyses of GWAS summary statistics by reducing data heterogeneity and errors. *Nature Comm*. 2021;12(1):1-10.
149. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet*. 2014;10:e1004383.
150. Fadason T, Ekblad C, Ingram JR, et al. Physical interactions and expression quantitative traits loci identify regulatory connections for obesity and type 2 diabetes associated SNPs. *Front Genet*. 2017;8:150.
151. Giambartolomei C, Zhenli Liu J, Zhang W, et al. A Bayesian framework for multiple trait colocalization from summary association statistics. *Bioinform*. 2018;34:2538-2545.
152. Yazar S, Alquicira-Hernandez J, Wing K, et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. *Science*. 2022;376:eabf3041.
153. Abugessaisa I, Ramiowski JA, Lizio M, et al. FANTOM enters 20th year: expansion of transcriptomic atlases and functional annotation of non-coding RNAs. *Nucl Acids Res*. 2021;49:D892-D898.
154. Crowley L, Cambuli F, Aparicio L, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. *Elife*. 2020;9:e59465.
155. Henry GH, Malewska A, Joseph DB, et al. A cellular anatomy of the normal adult human prostate and prostatic urethra. *Cell Rep*. 2018;25:3530-3542. e3535.

Table 1: Table of missense lead variants or variants that are in high linkage disequilibrium with lead variants.

Gene	Variant		Lead or LD with lead ¹	Risk Allele	Frequency ²	CADD	Variant functional consequence
	AA Change	rsID					
<i>ABCA6</i>	p.Cys1359Arg	rs77542162	Lead	Cysteine	0.99	28.7	ATP-binding cassette subfamily member A6. May play a role in macrophage lipid transport and homeostasis. Arginine allele disrupts protein stability ¹ .
<i>ABCG2</i>	p.Gly141Lys	rs2231142	Lead	Lysine	0.09	16.4	ATP-binding cassette subfamily member G2. Lysine allele of pGly141Lys causes internalization of ABCG2 ² , preventing secretion of urate ³ . p.Val12Met has not been associated with ABCG2 phenotype ⁴ .
	p.Val12Met	rs2231137	Lead (COJO)	Valine	0.94	2.4	
<i>ADH1B</i>	p.His48Arg	rs1229984	Lead	Histidine	0.03	13.1	Alcohol dehydrogenase 1B. The histidine allele causes rapid oxidation of alcohol ⁵ , predicted to increased depletion of the ATP pool and increase urate by ADP catabolism.
<i>ALDH2</i>	p.Asp504Lys	rs671	1.0 (EAS)	Glutamate	0.83 (EAS)	32.0	Aldehyde dehydrogenase 2. Glutamate allele causes increased ALDH2 activity, consistent with increased hypoxanthine and urate levels after ingestion of alcohol ^{6,7} .
<i>CPS1</i>	p.Thr1412Asn	rs1047891	Lead	Threonine	0.70	18.2	Carbamoyl phosphate synthase. Threonine allele associates with lower levels of blood arginine ⁸ .
<i>GCKR</i>	p.Leu446Pro	rs1260326	Lead	Leucine	0.41	13.2	Glucokinase regulatory protein. Leucine allele causes relaxation of inhibition of glucokinase ^{9,10} , predicted to increase glucose phosphorylation, deplete ATP pool and increase urate by ADP catabolism.
<i>GLS2</i>	p.Leu581Pro	rs2657879	1.0	Proline	0.21	15.2	Glutaminase 2. Regulated by METTL3.

<i>HNF4A</i>	p.Ala98Val	rs1800961	Lead (COJO)	Threonine	0.96	21.4	Proline allele associates with lower plasma glutamine levels ¹¹ . Hepatocyte nuclear factor 4A. Threonine variant reduces transactivation of the <i>ABCG2</i> promoter, predicted to reduce <i>ABCG2</i> levels and urate secretion ¹² .
<i>MC4R</i>	p.Val103Ile	rs2229616	1.0	Valine	0.99	18.5	Melanocortin 4 receptor. Isoleucine variant protective of obesity. Gain of function variant ¹³ . Likely reflects causal effect of obesity on gout.
<i>PNPLA3</i>	p.Ile148Met	rs738409	1.0	Isoleucine	0.78	13.7	Patatin-like phospholipase domain-containing protein 3 (adiponutrin). Methionine allele is loss of function and reduces hepatic VLDL secretion ¹⁴ .
<i>SH2B3</i>	p.Trp262Arg	rs3184504	1.0 (EAS/ AFR)	Tryptophan	0.46	10.7	SH2B adaptor protein 3. Negative regulator of cytokine signalling. Deficiency promotes monocyte proliferation upon stimulation ¹⁵ . Tryptophan allele is loss of function ¹⁶ .
<i>SLC17A1</i>	p.Thr269Ile	rs1165196	Lead	Isoleucine	0.56	8.5	Solute carrier family member 17A1, encodes NPT1. Secretory urate transporter. Isoleucine allele reduces urate transport activity ¹⁷ .
<i>SLC17A3</i>	p.Gly279Arg	rs56027330	0.99 (COJO)	Arginine	0.14	17.4	Solute carrier family member 17A3, encodes NPT3. Secretory urate transporter. Arginine allele reduces urate transport activity ¹⁸ .
<i>SLC2A9</i>	p.Gly25Arg	rs2276961	0.98 (COJO)	Arginine	0.53	2.3	Solute carrier family member 2A9, encodes GLUT9. Reuptake urate transporter. The variant does not influence urate transport activity ¹⁹ .
<i>SLC39A8</i>	p.Ala391Thr	rs13107325	Lead	Alanine	0.92	22.0	Encodes solute-carrier gene, a zinc / cadmium / manganese transporter. Increases

NF- κ B signalling in macrophages²⁰. Threonine allele slightly reduces transport activity²¹.

<i>SLCO1B1</i>	p.Val174Ala	rs4149056	Lead	Valine	0.84	25.1	Solute carrier organic anion transporter family member 1B1. Uptake transporter. Alanine allele reduces transporter activity ²² .
Gene function							
<i>ADO</i>	p.Gly25Trp	rs2236295	Lead	Glycine	0.63	24.1	2-aminoethanethiol dioxygenase. Forms hypotaurine.
<i>AP4E1</i>	p.Cys88Arg	rs2306331	1.0 (EAS)	Cysteine	0.53	17.3	Adaptor-related protein complex 4 subunit epsilon 1. Role in mediating vesicle formation in secretion and endocytosis.
<i>AQP10</i>	p.His123Tyr	rs6685323	1.0	Histidine	0.68	5.6	Aquaporin 10. Water-selective integral membrane channel.
<i>BSCL2</i>	p.Lys268Arg	rs6856	0.99	Lysine	0.81	5.7	Encodes endoplasmic reticulum transmembrane protein seipin. Important for lipid droplet morphology.
<i>CRIP3</i>	p.Ile188Thr	rs2242416	0.98	Isoleucine	0.42	21.1	Cysteine-rich protein 3.
<i>CUBN</i>	p.Ile2984Val p.Glu3002Gly	rs1801239 rs1801240	1.0	Valine Glycine	0.09	15.0 19.3	Cubilin. Intrinsic factor-vitamin B12 receptor. Range of physiological functions. Associates with megalin (LRP2) in proximal tubule of kidney to resorb filtered proteins ²³ .
<i>CTAGE9</i>	p.Leu398Val	rs202051647	1.0 (EAS)	Leucine	0.92	17.8	CTAGE family member 9. Predicted involved in endoplasmic reticulum to Golgi vesicle transport.
<i>DTL</i>	p.Ala394Val	rs3135474	1.0	Alanine	0.04	7.6	Denticleless E3 ubiquitin protein ligase homolog. Involved in protein ubiquitination.
<i>DDIT4L</i>	p.Lys180Arg	rs201713115	1.0	Arginine	0.09	22.9	DNA damage inducible transcript 4 like. Promotes autophagy via mTOR ²⁴ .
<i>EPB41</i>	p.Ala214Ile	rs111642750	Lead	Isoleucine	0.04	22.5	Erythrocyte membrane protein band 4.1.

							Involved in erythrocyte shape.
EVI5	p.Ile336Val	rs2391199	1.0	Isoleucine	0.91	4.3	Ecotropic viral integration site 5. Involved in endosome to Golgi transport.
FAM35A	p.Ser550Cys	rs11202365	0.99	Cysteine	0.36	22.8	Encodes shieldin complex subunit 2. Shieldin complex involved in DNA repair.
FGF21	p.Leu174Pro	rs739320	Lead	Leucine	0.37	5.9	Fibroblast growth factor 21. Hepatokine that regulates sugar intake and metabolism.
FRK	p.Gly122Arg	rs3756772	0.99	Arginine	0.42	19.3	Fyn related Src family tyrosine kinase
GLIS3	p.Pro456Gln	rs6415788	Lead	Proline	0.37	14.5	GLI-similar zinc finger protein family. Has a role in islet β -cell development ²⁵ .
INHBC	p.Arg322Gln	rs2229357	0.99	Arginine	0.81	19.6	Inhibin subunit beta C. Member of TGF- β superfamily. Inhibition of activin A signalling.
HNF1A	p.Ala98Val	rs1800574	Lead	Alanine	0.97	22.6	Hepatocyte nuclear factor 1A. The valine variant implicated in MODY3.
JMJD1C	p.Glu2535Asp	rs1935	Lead	Aspartate	0.51	11.2	Jumonji domain containing 1C a.k.a KDM3C. A histone demethylase.
KIAA0100	p.Val1373Gly	rs12602520	1.0	Glycine	0.07	15.9	Bridge-like lipid transfer protein family member 2 (BLTP2).
LRP2	p.Lys4094Glu	rs2075252	0.99	Glutamate	0.24	13.1	LDL receptor-related protein 2 (megalin). Associates with cubilin in kidney proximal tubule to resorb filtered proteins ²³ .
MLXIPL	p.Ala191Val	rs35332062	0.99	Alanine	0.88	19.4	MLX interacting protein like. Transcription factor, activates motifs of triglyceride synthesis genes.
	p.Gln203His	rs3812316	Lead	Histidine	0.88	17.1	
MFSD12	p.Tyr182His	rs2240751	Lead	Tyrosine	0.99	27.4	Major facilitator superfamily domain-containing 12. A mediator of cysteine transport ²⁶ .
NPHS2	p.Arg226Gln	rs61747728	Lead	Arginine	0.96	22.8	Encodes podocin, regulates glomerular permeability.
POM121	p.Pro955Ser	rs9955	Lead	Proline	0.87	1.1	Encodes a transmembrane nucleoporin.

							Inhibits macrophage LPS response by blocking NF- κ B translocation to the nucleus ²⁷ .
SH2B1	p.Thr171Ala	rs7498665	1.0	Alanine	0.33	12.8	SH2B adaptor protein 1. Involved in kinase activation and signalling.
SLC25A5	p.Leu111His	rs371749	Lead	Arginine	0.75	22.3	Solute carrier family member 25A5. Encodes ADP:ATP translocase 2 (ANT2) that mediates transport of ADP into the mitochondrial matrix. Drives proinflammatory macrophage activity ²⁸ .
SLC5A1	p.Asn51Ser p.Ala411Thr p.His615Gln	rs17683011 rs17683430 rs33954001	0.98	Serine Alanine Glutamine	0.06	20.2 15.7 5.4	Solute carrier family member 5A1. Encodes sodium / glucose cotransporter 1 (SGLT1). A haplotype of missense variants.
SLC5A9	p.Ala600Val	rs78427303	1.0 (COJO)	Alanine	0.91	0.0	Encodes sodium/glucose transporter SGLT4.
SOS2	pPro191Arg	rs72681869	Lead	Arginine	0.99	22.5	SOS Ras/Rho guanine nucleotide exchange factor 2.
TSPAN6	p.Ala108Thr	rs1802288	Lead	Alanine	0.81	26.0	Tetraspanin 6. Implicated in production of extracellular vesicles ²⁹ .
UPF3A	p.Arg64Lys	rs3752105	0.99	Lysine	0.26	15.2	UPF3A regulator of nonsense-mediated mRNA decay.

Candidate causal variants were drawn from **Table S25** as either a lead variant (including from conditional COJO analysis) or in very strong linkage disequilibrium ($r^2 \geq 0.98$) with a lead variant (including from conditional COJO analysis). 1, in European, unless otherwise stated; 2, risk allele in European, unless otherwise stated. First section, genes with candidate causal missense variants with information available on impact of the variant on protein function and phenotype; Second section, the remaining genes.

1. He B, Kang S, Chen Z, et al. Hypercholesterolemia risk associated Abca6 does not regulate lipoprotein metabolism in mice or hamster. *Biochimica et Biophysica Acta* 2021;1866:159006.
2. Basseville A, Tamaki A, Ierano C, et al. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. *Cancer Res.* 2012;72:3642-3651.
3. Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. *Proc Natl Acad Sci.* 2009;106:10338-10342.
4. Cleophas M, Joosten L, Stamp L, et al. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. *Pharmacogen Pers Med.* 2017;10:129142.
5. Takeshita T, Mao X-Q, Morimoto K. The contribution of polymorphism in the alcohol dehydrogenase β subunit to alcohol sensitivity in a Japanese population. *Hum Genet.* 1996;97:409-413.
6. Farrés J, Wang X, Takahashi K, et al. Effects of changing glutamate 487 to lysine in rat and human liver mitochondrial aldehyde dehydrogenase. A model to study human (Oriental type) class 2 aldehyde dehydrogenase. *J Biol Chem.* 1994;269:13854-13860.
7. Yamanaka H, Kamatani N, Hakoda M, et al. Analysis of the genotypes for aldehyde dehydrogenase 2 in Japanese patients with primary gout. *Adv Exp Med Biol.* 1994;370:53-56.
8. Pearson DL, Dawling S, Walsh WF, et al. Neonatal pulmonary hypertension: urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. *NEJM.* 2001;344:1832-1838.
9. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. *Hum Mol Genet.* 2009;18:4081-4088.
10. Rees M, Wincovitch S, Schultz J, et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. *Diabetologia.* 2012;55:114-122.
11. Kettunen J, Demirkan A, Würtz P, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat Comm.* 2016;7:11122.
12. Tin A, Marten J, Kuhns VLH, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. *Nat Genet.* 2019;51:1459-1474.
13. Xiang Z, Litherland SA, Sorensen NB, et al. Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist. *Biochem.* 2006;45:7277-7288.
14. Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. *J Hepatol.* 2012;57:1276-1282.
15. Allenspach EJ, Shubin NJ, Cerosaletti K, et al. The autoimmune risk R262W variant of the adaptor SH2B3 improves survival in sepsis. *The J Immunol.* 2021;207:2710-2719.
16. Wang W, Tang Y, Wang Y, et al. LNK/SH2B3 loss of function promotes atherosclerosis and thrombosis. *Circ Res.* 2016;119:e91-e103.
17. Iharada M, Miyaji T, Fujimoto T, et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 protein) is a cl⁻-dependent urate exporter. *J Biol Chem.* 2010;285:26107-26113.

18. Jutabha P, Anzai N, Kimura T, et al. Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms. *J Pharmacol Sci.* 2011;115:249-253.
19. Hurba O, Mancikova A, Krylov V, et al. Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout. *PLoS One.* 2014;9:e107902.
20. Hall SC, Smith DR, Dyavar SR, et al. Critical role of zinc transporter (ZIP8) in myeloid innate immune cell function and the host response against bacterial pneumonia. *J Immunol.* 2021;207:1357-1370.
21. Fujishiro H, Miyamoto S, Sumi D, Kambe T, Himeno S. Effects of individual amino acid mutations of zinc transporter ZIP8 on manganese-and cadmium-transporting activity. *Biochem Biophys Res Comm.* 2022;616:26-32.
22. Türkmen D, Masoli JA, Kuo CL, et al. Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men. *Br J Clin Pharmacol.* 2022;88:3230-3240.
23. Zhao B, Tu C, Shen S, Qu J, Morris ME. Identification of potential megalin/cubilin substrates using extensive proteomics quantification from kidney megalin-knockdown mice. *AAPS J.* 2022;24:109.
24. Simonson B, Subramanya V, Chan MC, et al. DDIT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress. *Sci Signaling.* 2017;10:eaaf5967.
25. Scoville DW, Jetten AM. GLIS3: A critical transcription factor in islet β -cell generation. *Cells.* 2021;10:3471.
26. Adelmann CH, Traunbauer AK, Chen B, et al. MFSD12 mediates the import of cysteine into melanosomes and lysosomes. *Nature.* 2020;588:699-704.
27. Ge W, Yue Y, Xiong S. POM121 inhibits the macrophage inflammatory response by impacting NF- κ B P65 nuclear accumulation. *Exp Cell Res.* 2019;377:17-23.
28. Moon J-S, da Cunha FF, Huh JY, et al. ANT2 drives proinflammatory macrophage activation in obesity. *JCI Insight.* 2021;6:e147033.
29. Ghossoub R, Chéry M, Audebert S, et al. Tetraspanin-6 negatively regulates exosome production. *Proc Natl Acad Sci.* 2020;117:5913-5922.

Table 2: Table of candidate immune-priming lncRNAs.

Gene	lncRNA	Lead Variant		Normalized Prioritization Score		Gene Function
		rsID	Chr:Position	Gene	lncRNA	
<i>AUH</i>	<i>RP11-305L7.7</i>	rs2387099	9:91223542	4.7	1.2	3-methylglutaconyl-CoA hydratase. In leucine degradation pathway. Located in mitochondrial membrane. Binds to AU-rich elements in 3-UTRs of rapidly decaying RNAs.
<i>BAG4</i>	<i>RP11-350N15.4</i> <i>RP11-350N15.5</i>	rs4537271	8:38040503	4	1 3	Bcl2-associated athanogene 4. Negative regulator of apoptosis. <i>BAG4</i> and <i>RP11-350N15.5</i> have whole blood eQTL.
<i>CPEB2</i>	<i>LINC00504</i> <i>CPEB-DT (DRAIR)</i>	rs12646450	4:14943190	3 ^a	2 ^a 1 ^a	Cytoplasmic polyadenylation element binding protein 2. <i>DRAIR</i> induces proinflammatory macrophages ¹ .
<i>DGAT2</i>	<i>RP11-535A19.2</i>	rs10899113	11:75757419	5	2	Diacylglycerol acyl transferase-2. Connects diacylglycerol to long-chain fatty acyl-CoA in triglyceride synthesis. <i>DGAT2</i> and <i>RP11-535A19.2</i> both have whole blood eQTL.
<i>IK</i>	<i>CH17-140K24.6</i>	rs2256547	5:139996011	4	1	Cytokine implicated in immunoregulation of lupus and inflammatory arthritis ² .
<i>KLF11</i>	<i>RP11-254F7.2</i>	rs10165255	2:10199601	4	1.2 ^b	Kruppel like factor 11. Implicated in NFκβ signalling ³ .
<i>LAMC1</i>	<i>RP11-181K3.4</i>	rs6660111	1:183045154	3.5	0	Laminin gamma 1. Extracellular matrix glycoprotein.
<i>MAST3</i>	<i>CTD-3149D2.3</i>	rs273496	19:18241857	4	1	Microtubule-associated serine/threonine-protein kinase gene-3. Implicated in TLR4 signalling and inflammatory

<i>NAPG</i>	<i>RP11-883A18.3</i>	rs489837	18:10485360	4	1	response via NFκβ ² . N-ethylmaleimide-sensitive factor attachment protein gamma. Aka gamma-SNAP. Regulates endosomal trafficking of transferrin ⁴ .
<i>PROCA1</i>	<i>RP11-20B24.7</i>	rs9896098	17:27008721	6	3	Protein interacting with cyclin A. Predicted to be involved in lipid metabolism.
<i>SLC22A4</i>	<i>AC116366.6</i> <i>AC063976.7</i>	rs7705189	5:132287665	4	3 2 ^c	<i>SLC22A4</i> encodes OCTN1, that transports the antioxidant ergothioneine into cells.
<i>YAF2</i>	<i>RP11-328C8.2</i> <i>RP11-351C21.2</i>	rs11181466	12:42370879	4	2 1	YY1-associated factor 2. Is a component of Polycomb repressive complex 1 (PRC1).

Candidate immune-priming lncRNAs were extracted from **Table S10** based on the lead variant having a cis-eQTL for both a lncRNA and a protein-coding gene with a high prioritization score in **Table S30**. SNP positions are noted in human genome build GRCh38 coordinates. a, prioritization score used rs28407119 (European male-only lead variant) as the locus SNP. b, prioritization score used rs4669524 (trans-ancestry full (combined sexes) lead variant) as the locus SNP. c, prioritization score used rs112537099 (European male-only lead variant) as the locus SNP.

1. Reddy MA, Amaram V, Das S, et al. lncRNA DRAIR is downregulated in diabetic monocytes and modulates the inflammatory phenotype via epigenetic mechanisms. *JCI Insight*. 2021;6:e143289.
2. Park H-L, Lee S-M, Min J-K, et al. IK acts as an immunoregulator of inflammatory arthritis by suppressing TH17 cell differentiation and macrophage activation. *Sci Rep*. 2017;7:40280.

3. Fan Y, Guo Y, Zhang J, et al. Krüppel-like factor-11, a transcription factor involved in diabetes mellitus, suppresses endothelial cell activation via the nuclear factor- κ B signaling pathway. *Arterioscler, Thromb Vasc Biol.* 2012;32:2981-2988.
4. Inoue H, Matsuzaki Y, Tanaka A, et al. γ -SNAP stimulates disassembly of endosomal SNARE complexes and regulates endocytic trafficking pathways. *J Cell Sci.* 2015;128:2781-2794.

List of Figures

Figure 1: Numbers of significant loci and independent signals, across the ancestry-specific and trans-ancestry analyses and in the full (combined sexes), male-only, and female-only analyses.

Figure 2: Association of polygenic risk score with gout in European participants of the UK Biobank in combined sexes, men, and women.

Figure 3: Genetic correlation between the European gout GWAS and UK Biobank GWAS traits.

Figure 4: Functional and pathway enrichment analyses of gout candidate genes.

Figure 5: Genes prioritized for a role in gouty inflammation.

Figure 6: XDH expression and xanthine oxidoreductase activity in the prostate.

Figure 7: Mendelian randomization of CHIP vs gout for either all CHIP, DNMT3A CHIP, or TET2 CHIP.

Figure 8: DGAT2: Example of genome organization at a candidate immune-priming lncRNA locus.

Figure 9: Linking of insulin signalling, the Krebs cycle and epigenomic reprogramming with candidate gout-associated genes.




Figure 1: Numbers of significant loci and independent signals, across the ancestry-specific and trans-ancestry analyses and in the full (combined sexes), male-only, and female-only analyses. A) summarizes the cohorts used, the GWAS done and loci detected. B) shows a Venn diagram of the overlap between significant loci across the amalgamated full, male-only, and female-only GWAS. C) shows an upset plot of the overlap between the significant independent signals in the single-ancestry and trans-ancestry analyses for the full cohort.




Figure 2: Association of polygenic risk score with gout in European participants of the UK Biobank in combined sexes, men and women. The top panel (A) shows the PRS bin distribution, the middle panel (B) the gout prevalence in different PRS bins and the bottom panel (C) the risk for gout of the different PRS bin compared to the most common bin (D) the area under the receiver operating characteristic curve graphs.

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




Figure 3: Genetic correlation between the European gout GWAS and UK Biobank GWAS traits. In all plots, each point represents the result of a genetic correlation analysis between our European gout GWAS and one of the 934 UK Biobank GWAS traits. Non-significant results are shown as transparent plot points for clarity. A. Volcano plot of genetic correlation between gout European GWAS results and 934 UK Biobank GWAS traits. Points are coloured based on whether the equivalent correlation between the UK Biobank serum urate GWAS and trait of interest was significant ($P < 5.35 \times 10^{-5}$). B. Linear relationship between the genetic correlation results of the European gout GWAS and the UK Biobank serum urate GWAS. Points are coloured based on whether they were significant in both, one, or neither of the genetic correlation analyses. C. Genetic correlation values (r_g) across 27 trait categories. Significant correlations are highlighted.

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




Figure 4: Functional and pathway enrichment analyses of gout candidate genes. The DAVID database was used to identify GO Biological Function term, KEGG and REACTOME pathways enriched in the gout GWAS dataset. Significance (FDR) of the enrichment is denoted on the y-axis, size of the circle denotes number of genes contributing to the enrichment term




Figure 6: *XDH* expression and xanthine oxidoreductase activity in the prostate. A) Plots of genetic association at the *XDH* locus with gout (European full analysis, left) and serum urate in Europeans (UK Biobank; right). Each genetic variant is represented by a single dot plotted according to genomic position on the x-axis with strength of evidence for association ($-\log_{10}(P)$) on the y-axis. The lead variant is highlighted with purple diamond; other variants are colored according to their linkage disequilibrium with the lead variant (strong (red) to weak (dark blue)). B) The European male gout (top left) GWAS signal co-localizes with *XDH* expression in prostate tissue (GTEx v8; bottom left), but not with female gout GWAS signal (top right). Shown also is the expression signal of *XDH* in the liver (GTEx v8; bottom right). C) XOR activity and urate levels in prostate, liver and seminal vesicle tissue from seven-week old C57Bl/6 male mice. Kruskal-Wallis test was used to determine the difference between tissues, significant. D-E) Bar plots showing the percentage of cells expressing *XDH* in a given cell cluster, alongside three urate transporter genes (*ABCG2*, *SLC2A9*, *ABCC4*) in prostate cell clusters. Single cell RNA-seq data were obtained from Crowley et al. (D) Henry et al. (E).




Figure 7: Mendelian randomization of CHIP vs gout. Results of CHIP MR for either all CHIP, DNMT3A CHIP, or TET2 CHIP. Plots A, C, and E show the relative effect sizes of the different CHIP-associated variants on gout, with overlaid lines indicating the MR estimates from either weighted median, inverse variance weighted, or MR-Egger regression. Plots B, D, and F show the MR estimates as forest plots, including the MR-Egger intercept for each model.




Figure 8: DGAT2: Example of genome organization at a candidate immune-priming lncRNA locus. ENCODE H3K4me3 signal track from CD14+ monocytes indicates enrichment at the promoters of DGAT2, the lncRNA RP11-535A19.2 and UVRAG. ENCODE CTCF signal track from neutrophils and CD14+ monocytes indicates CTCF binding at the SNP rs11236533. Genehancer connections are indicated in green and illustrate physical connections (Hi-C) between the rs11236533 which disrupts a CTCF site and additional maximally associated SNPs at two Genehancer regulatory elements. Red and blue dots indicate the CpG locations that are associated with co-localized meQTL and the colour denotes direction of effect of the gout risk allele (red = higher methylation, blue = lower methylation)

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




Figure 9: Linking of insulin signalling, the Krebs cycle and epigenomic reprogramming with candidate gout-associated genes. Candidate genes are encircled in bold lines, CHIP-implicated genes in red bold lines.